Healthcare & Life Sciences — April 16, 2026

Phase 2 Study of LY4005130 for Severe Alopecia Areata

The National Institutes of Health has registered a Phase 2 clinical trial (NCT07533006) on ClinicalTrials.gov evaluating LY4005130, an investigational intravenous drug, in adults with severe alopecia areata. The approximately 48-week randomized controlled trial will assess efficacy, tolerability, safety, and pharmacokinetics of LY4005130 versus placebo. This registry entry provides public transparency on the clinical investigation but does not constitute regulatory approval, authorization, or impose compliance obligations.

Multicenter RCT: Laparoscopic Staging for Stage III Gastric Cancer

The NIH has registered a new multicenter randomized controlled trial (NCT07533825) on ClinicalTrials.gov investigating laparoscopic staging-guided therapy for patients with clinical stage III gastric cancer. The study will evaluate the impact on overall survival, surgical conversion rate, and peritoneal metastasis rate, comparing laparoscopic staging-guided therapy against treatment without laparoscopic exploration. Enrollment begins April 16, 2026.

Fexuprazan 20mg Phase 4 Trial for NSAID-Induced Peptic Ulcer Prevention

NIH ClinicalTrials.gov registered a Phase 4 clinical trial (NCT07533266) for Fexuprazan 20mg as a preventive treatment for NSAID-induced peptic ulcers. The study will enroll participants using NSAIDs and compare the non-inferiority of Fexuprazan 20mg to Lansoprazole 15mg over 8 weeks. The trial is listed with an estimated start date and targets completion by April 2026.

Respiratory and Haemodynamic Effects of Conscious Sedation With Dexmedetomidine for a TAVI Procedure

NIH registered clinical trial NCT07532733 comparing dexmedetomidine versus propofol with remifentanil for conscious sedation during transcatheter aortic valve implantation (TAVI). The study aims to evaluate intraoperative respiratory and hemodynamic tolerance in elderly patients with severe aortic stenosis. Trial status dated April 16, 2026.

Study Investigates IBS During Fertility Treatments

The NIH ClinicalTrials.gov registry has posted a new observational study (NCT07533968) investigating the impact of fertility treatments on irritable bowel syndrome (IBS) symptoms in women. The study focuses on two cohorts: women with polycystic ovary syndrome (PCOS) beginning their first IVF cycle and women undergoing social egg freezing. Researchers will use questionnaires to track changes in IBS prevalence, severity, and associated anxiety and depression scores across multiple subgroups.

Effect of Preoperative Sensory Modulation Room on Pain, Anxiety, and Sleep in Kidney Transplant Patients

NIH registered clinical trial NCT07533669 evaluating whether preoperative exposure to a sensory modulation room influences postoperative pain, anxiety, and sleep outcomes in adult living kidney donors and recipients. The prospective study compares participants receiving preoperative sensory modulation (intervention group) to those receiving standard preoperative care (control group). Estimated study completion date is April 16, 2026.

Primed to Thrive: Mindfulness and Meditation Trial for Workplace Well-Being

NIH registered an interventional clinical trial (NCT07534683) evaluating whether combining mindfulness education with daily guided meditation via smartphone application improves psychological well-being and workplace outcomes compared with education alone. Adult employees will be randomized to receive meditation plus educational materials or a waitlist control, with assessments over approximately 12 weeks using the Utrecht Work Engagement Scale (UWES-9) as the primary outcome.

Observational Trial of Unapproved/Uncleared FDA Device

NIH ClinicalTrials.gov registered observational trial NCT07533201 studying an unapproved or uncleared FDA device. The study is classified as observational, meaning researchers will collect data on device performance or safety outcomes without intervening. Registered April 16, 2026.

Randomized Trial Comparing PTCD Catheter Removal vs Retention After Pancreaticoduodenectomy in Obstructive Jaundice

NIH registered a multicenter prospective randomized controlled trial (NCT07532759) comparing intraoperative PTCD catheter removal versus retention during pancreaticoduodenectomy in patients with obstructive jaundice. The trial will enroll participants with pancreatic head cancer, periampullary neoplasms, and biliary tract neoplasms to evaluate postoperative complications including bile leak and severe morbidity within 90 days.

Acute Amino Acid Response of Proprietary Beverages

The National Institutes of Health registered clinical trial NCT07534020 on ClinicalTrials.gov. The trial evaluates post-meal amino acid response to four proprietary protein beverage formulations (carbonated test protein beverage, standard protein beverage, control protein beverage, and Study Product D) in generally healthy adults.

Wyoming Launches Community Naloxone Resource Map

The Wyoming Department of Health announced the Community Naloxone Resource Map, an online tool helping residents find naloxone (Narcan) at no cost at local organizations. The map displays groups across Wyoming that provide free naloxone, which reverses opioid overdose effects. Organizations wishing to be included can request addition via a provided form, and businesses or groups can also order naloxone at no cost from WDH for emergency response or distribution.

AI-Assisted 4-Week Psychodynamic and Cognitive Behavioral Therapy Via Smartphone for Social Anxiety: Randomized Pilot Study (STePS-Ai)

NIH's ClinicalTrials.gov registered a new randomized pilot study comparing AI-assisted psychodynamic therapy and cognitive behavioral therapy delivered via smartphone for social anxiety disorder. The study will enroll participants in three arms: AI-guided psychodynamic therapy, AI-guided cognitive behavioral therapy, or waitlist control. Participants will complete weekly online questionnaires to monitor anxiety and mood changes over the 4-week intervention period.

FMT for Advanced Tumor Cachexia, Phase 2

NIH has registered a prospective, multicenter, single-arm Phase 2 clinical study (NCT07533227) to evaluate the efficacy and safety of fecal microbiota transplantation (FMT) capsules in treating advanced tumor cachexia in cancer patients. The trial is listed on ClinicalTrials.gov as a reference document.

Phase 4 Suzetrigine Trial for Opioid-Free Cesarean Recovery

NIH registered Phase 4 clinical trial NCT07534709 to evaluate suzetrigine as an adjunctive analgesic for opioid-free recovery following cesarean delivery. The randomized, placebo-controlled study will assess whether suzetrigine added to standard multimodal analgesia increases the proportion of patients remaining opioid-free through 72 hours post-surgery. Participants receive standardized pain management with acetaminophen, NSAIDs, and neuraxial morphine, with opioid rescue medication available for breakthrough pain.

ACSS Surgical Approaches and Dysphagia Comparison Study

NIH registered an observational clinical study (NCT07533864) comparing two anterior cervical spine surgery (ACSS) approaches—Smith-Robinson versus strap-splitting—for their effects on dysphagia (swallowing difficulties) and voice changes. The study will enroll participants assigned to either approach based on surgeon preference, with follow-up questionnaires assessing swallowing and speaking outcomes. This registry entry documents an active clinical investigation on a common spinal procedure with known swallowing-related complications.

Effect of Oral Probiotics on Allergic Rhinitis Symptoms and Quality of Life

NIH registered a clinical trial (NCT07532837) examining oral probiotics versus placebo for treating allergic rhinitis symptoms and quality of life. The study will evaluate Lactobacillus rhamnosus F-1 and Lactobacillus reuteri GL-104 in patients with allergic rhinitis, an inflammatory nasal condition affecting sleep, work productivity, and concentration.

Comparison of Maxillary Dental Expansion Using Smartee Clear Aligner With and Without S11 Expander: A Randomized Clinical Trial

The NIH's ClinicalTrials.gov has registered a randomized clinical trial (NCT07533682) comparing maxillary dental expansion using Smartee Clear Aligners with and without the S11 expander. The trial will use cone beam computed tomography (CBCT) to evaluate orthodontic expansion and tooth movement in patients with posterior crossbite requiring maxillary arch expansion.

Evaluation of the Effect of a PRECEDE-PROCEED Model-Based Laughter Yoga-Supported Education Program on Peer Bullying

NIH registered a clinical trial (NCT07534566) evaluating a laughter yoga-supported education program based on the PRECEDE-PROCEED Model to reduce peer bullying among adolescents. The study targets middle school students and examines effects on awareness of peer bullying and psychosocial well-being. The trial involves health education and laughter yoga interventions as comparators.

Treatment of Cognitive and Sensorimotor Deficits in Parkinson's Disease With High Definition Transcranial Direct Current Stimulation

NIH ClinicalTrials.gov registered a Phase 1/2 interventional study (NCT07534397) evaluating high-definition transcranial direct current stimulation (tDCS) for treating cognitive and sensorimotor deficits in Parkinson's disease patients. The trial will enroll participants receiving either active tDCS or sham stimulation to assess effects on verbal retrieval, cognition, and motor control. Estimated start date is April 16, 2026.

Web-Based Mindful Parenting RCT for Adoptive Parents

A pilot randomized controlled trial evaluating AdoptMindful2Care@Web, a 9-module web-based post-adoption psychological intervention grounded in mindful parenting principles for adoptive parents, has been registered on ClinicalTrials.gov (NCT07534111). The study targets parenting stress and positive mental health as primary outcomes using a web-based intervention delivery format. This registry entry documents the study design, conditions (Parenting Stress, Positive Mental Health), and intervention details for research transparency purposes.

Tafenoquine Combinations for Improved Radical Cure Efficacy of Plasmodium Vivax

NIH registered ClinicalTrials.gov Study NCT07533136, a Phase 4 trial evaluating tafenoquine-based combination therapies for radical cure of uncomplicated Plasmodium vivax malaria in Thai adults. The study compares dihydroartemisinin-piperaquine or artemether-lumefantrine with tafenoquine against chloroquine plus tafenoquine over a 6-month follow-up period to assess recurrence prevention efficacy.

Information Collection: Religious Nonmedical Health Care Institutions and Transplant Programs Conditions of Participation

CMS announces an opportunity for public comment on two proposed information collections under the Paperwork Reduction Act. The first collection covers Religious Nonmedical Health Care Institutions (RNHCIs) Conditions of Participation with an estimated annual burden of 824 hours and cost of $38,113. The second covers Transplant Programs Conditions of Participation with an estimated annual burden of 3,340 hours and cost of $352,462. Comments must be received by the OMB desk officer by May 18, 2026.

Wilfactin Supply Tensions: Use Therapeutic Alternatives

ANSM has issued guidance advising healthcare professionals to limit use of Wilfactin (factor Willebrand) to emergency situations and prophylaxis for patients under 18 with contraindications to alternatives, due to ongoing supply tensions at manufacturer LFB. The agency provides a detailed table of therapeutic alternatives (Eqwilate, Voncento, Veyvondi) organized by indication and patient age group.

Disciplinary Records Database Access Notice

The Wisconsin Department of Safety and Professional Services (DSPS) provides public online access to its Reports of Decision database containing disciplinary orders issued by credentialing authorities since November 1998. Users must agree to terms acknowledging the database reflects information at a specific point in time, may contain discrepancies from original documents, and requires citing the LS case number, order date, and respondent name to obtain copies.

DOH Offers Review of Disciplinary Actions Based on Unconstitutional Drug Possession Statute

The Washington State Department of Health announced it will review adverse administrative actions taken against individuals where those actions were based solely or in part on convictions under RCW 69.50.4013(1), the simple drug possession statute ruled unconstitutional by the Washington Supreme Court in Washington v. Blake. Affected individuals may contact DOH at SCBlakeDecision@doh.wa.gov to request review of their case.

Thermal Spa Programme for Knee Osteoarthritis, 3-Week Study (NCT07534189)

The NIH ClinicalTrials.gov registry has registered a prospective cohort study (NCT07534189) evaluating a 3-week thermal spa treatment programme for patients with symptomatic knee osteoarthritis. The study will assess knee joint movement using wearable inertial sensors (Xsens), along with secondary outcomes including pain, physical function, quality of life, and blood transcriptomic profiles. Participants will be evaluated at baseline, post-treatment, and at 3- and 12-month follow-up visits.

Technology Addiction Linked to Adolescent Activity and Attention

NIH ClinicalTrials.gov has registered a new observational study (NCT07532720) examining the relationship between technology addiction and physical activity and attention levels in adolescents. The study evaluates whether higher levels of technology addiction are associated with lower physical activity and reduced attention. Conditions include Technology Addiction, Adolescent Health, and Attendance Level.

PRECISE Phenotyping to Guide Therapies for Coronary Microvascular Dysfunction

NIH's ClinicalTrials.gov registered a new Phase 3 clinical trial (NCT07533747) evaluating Empagliflozin 10mg for Coronary Microvascular Dysfunction (CMD). The trial aims to study heart energy metabolism in patients with CMD, a condition causing chest pain and shortness of breath without arterial blockages. No widely available proven treatments currently exist for CMD, making this a significant research effort targeting an unmet medical need.

Pediatric Persistent Hypoglycemia Risk Factors at Sohag University Hospital

NIH registered a new observational clinical trial (NCT07533318) at Sohag University Hospital in Egypt studying endocrine, metabolic, and genetic risk factors of pediatric persistent hypoglycemia. The study will enroll 24 pediatric patients experiencing hypoglycemia beyond the first 3 days of life. Clinical investigators conducting pediatric metabolic research should be aware of this registry entry as part of ongoing surveillance of active hypoglycemia studies.

Holmium Laser Versus Conventional TURBT for Non-Muscle-Invasive Bladder Cancer: Randomized Controlled Trial, 100 Patients

NIH ClinicalTrials.gov registered a prospective randomized controlled trial (NCT07534631) comparing holmium laser en-bloc resection (HoLERBT) with conventional transurethral resection (cTURBT) for treatment of non-muscle-invasive bladder cancer. A total of 100 patients will be randomized 1:1. The primary outcome is quality of pathological specimen assessed by presence of detrusor muscle. Secondary outcomes include perioperative complications, operative time, obturator nerve reflex, bladder perforation, positive surgical margins, persistent disease at second-look TURBT, and recurrence rates at 3 and 12 months.

Diode Laser-Assisted Periodontal Therapy in Kidney Transplant Recipients

NIH has registered a new clinical trial (NCT07532694) on ClinicalTrials.gov evaluating diode laser-assisted non-surgical periodontal therapy in 80 kidney transplant recipients with periodontitis. The randomized controlled trial will compare scaling and root planing (SRP) with adjunctive diode laser therapy versus SRP alone. The study will assess clinical periodontal parameters, blood biomarkers, radiographic findings, and subgingival microbiome profiles at baseline and during follow-up through April 2026.

Kinesiophobia and Adhesive Capsulitis Observational Trial NCT07534527

NIH ClinicalTrials.gov registered observational study NCT07534527 investigating the relationship between kinesiophobia (fear of movement) and pain, range of motion, disability, and quality of life in patients with adhesive capsulitis (frozen shoulder). The study will involve physical examination and questionnaire-based assessment; no interventions are administered.

NECC Peer Support Observational Study for Neuroendocrine Cervical Cancer Patients

NIH registered an observational study (NCT07532954) titled 'The Impact Of A Patient Support Community On Patients With Neuroendocrine Cervical Cancer' on ClinicalTrials.gov. The study aims to learn about the effects of a participant support community on illness perception, emotional well-being, and feelings of isolation among participants with NECC using questionnaire-based interventions. No regulatory obligations or compliance requirements are imposed by this registry entry.

Internet-Based CBT for Anxiety and Depression, Singapore, NCT07532551

NIH's ClinicalTrials.gov has registered a clinical trial (NCT07532551) in Singapore evaluating Internet-based Cognitive Behavioural Therapy (iCBT) for adults with mild-to-moderate anxiety and/or depression. The randomized controlled trial will compare guided iCBT to usual care (traditional CBT) to assess clinical effectiveness, cost-effectiveness, and acceptability. Participants will receive structured digital modules with therapist support. The trial is expected to complete in April 2026.

Modular Neurological Examination for Early Risk Detection

NIH's ClinicalTrials.gov registered observational study NCT07533162 to validate a modular neurological screening tool for infants. The study evaluates the Hammersmith Infant Neurological Examination (HINE) and a novel modular tool requiring approximately 15 minutes to administer, aimed at early identification of infants requiring further neurological evaluation. The research focuses on infants from birth to 24 months across both low and high-risk populations for neurological damage.

Therapeutic Touch and Acupressure on Depressive Symptoms (NCT07532512)

NIH ClinicalTrials.gov registered a new study (NCT07532512) investigating therapeutic touch and acupressure as interventions for mild-to-moderate depressive symptoms. The randomized controlled trial will enroll participants receiving either eight therapeutic touch sessions or eight acupressure sessions over four weeks. Acupressure points include Yintang (EX-HN3), Shenmen (HT7), and Neiguan (PC6).

Early Pregnancy Behavioral Patterns and Gestational Diabetes Risk

NIH ClinicalTrials.gov has registered a prospective nested randomized pilot trial (NCT07534670) examining how early-pregnancy chronobehavioral patterns including sleep irregularity, physical activity, and meal timing influence continuous glucose dynamics and gestational diabetes mellitus risk. The TOFFFY substudy at KK Women's and Children's Hospital, Singapore will enroll 140 pregnant women without pre-existing diabetes at 13 weeks gestation or less.

CMS Finalizes Medicare Advantage and Part D 2027 Policies with 5.33% Growth Rate

CMS released a final rule and final rate notice for Medicare Advantage and Part D programs for contract year 2027. The final growth rate is 5.33%, up from the projected 4.97%, providing modest relief to MA plans. Key policy changes include removal of the Health Equity Index from Star Ratings, elimination of 11 of 12 proposed Star measure cuts, finalization of supplemental benefits debit-card provisions, and new marketing rules for agents and brokers. CMS also proposed risk model updates that would reduce MA risk scores by 3.32% in 2027, which stakeholders have challenged.

CMS LEAD Model Creates Specialist ACO Participation Pathways

Benesch attorneys analyze CMS's Long-term Enhanced ACO Design (LEAD) Model, which creates new pathways for specialist physicians to participate in Medicare ACO programs beyond traditional fee-for-service arrangements. The model offers two participation options—Participant Provider (full ACO membership with shared savings/losses) or Preferred Provider (contract-based collaboration)—alongside flexible payment structures including Non-Primary Care Capitation and Advanced Payment Option.

Federal Circuit Affirms Noninfringement on Blood Culture Patents

The Federal Circuit affirmed judgment of noninfringement for Kurin, Inc. in a patent dispute with Magnolia Medical Technologies over blood culture contamination reduction devices. The court held that claim 1 of the '483 patent requires separate "seal member" and "vent" structures, and that "diverter" in the '001 patent is a means-plus-function term that Kurin's device does not satisfy.

Healthcare Technology M&A Pulse Newsletter - April 2026

Bass, Berry & Sims PLC published its quarterly Healthcare Technology M&A Pulse Newsletter covering Q1 2026. The publication analyzes deal activity, regulatory developments, and trends at the intersection of healthcare and technology. This is a law firm newsletter providing market intelligence to clients and industry participants on digital health transactions.

Recent Disciplinary Actions by Quarter - Dentists and Dental Hygienists

The North Carolina State Board of Dental Examiners posted recent disciplinary actions taken against licensed dentists and dental hygienists. Actions include consent orders, reprimands, summary license suspensions, indefinite suspensions, conditional reinstatements, and probations spanning Q1 2026 through Q4 2024. Disciplinary orders remain public records accessible via the Board's license verification system.

Mississippi Dental Practice Act, Regulations, and Ethics Codes

The Mississippi State Board of Dental Examiners maintains an online resource page providing links to the Mississippi Dental Practice Act, regulations adopted by the board, public hearing guidelines, proposed amendments to board regulations, and ethics codes from the American Dental Association and American Dental Hygienists Association. The page serves as a central compliance resource for licensed dental professionals in Mississippi.

Public Disciplinary Orders Listed

Public Disciplinary Orders Listed

Measles Exposure Advisory at Mt Hood Community College, Gresham - April 13

Oregon Health Authority and Multnomah County public health officials have identified a new measles exposure location at Mt Hood Community College, Gresham Campus Academic Center Building 17. Individuals present at the location between 10 a.m. and 1:50 p.m. on Monday, April 13, 2026, may have been exposed. Officials are urging those potentially exposed to contact a healthcare provider to determine immunity status based on vaccination records, age, or laboratory evidence.

Quarterly Professional License Disciplinary Action Reports 2017-2026

The Alaska Division of Corporations, Business & Professional Licensing (CBPL) published its quarterly index of disciplinary actions for all professional licenses regulated by the division, covering 2017 through Q1 2026. The webpage provides links to PDF reports organized by quarter, with separate annual reports for 2017-2019. Individual disciplinary action documents are available via the Search Professional Licenses webpage, though upload of specific actions may take up to 60 days.

Oregon Medical Board Disciplinary Actions December 2025 - January 2026

The Oregon Medical Board issued its disciplinary action report covering December 16, 2025 through January 15, 2026. The report summarizes various actions including non-disciplinary Consent Agreements for re-entry, Stipulated Orders imposing civil penalties up to $10,000, license revocations, and terminations of prior corrective action agreements. Actions involve physicians (MD), physician assistants (PA), and acupuncturists (LAc) licensed in Oregon.

Oregon Medical Board Disciplinary Actions: 6 Licensee Actions Including Interim Orders

The Oregon Medical Board issued a Board Action Report documenting 6 licensee actions between November 16 and December 15, 2025. Actions include 2 Interim Stipulated Orders for emergency voluntary withdrawal from practice pending investigation (Crane, Sobotka), 3 Orders Terminating Consent Agreements for Re-Entry to Practice (Bouressa, Kameda-Smith, Zhang), and 1 Notice of Proposed Disciplinary Action (McEwen). Affected licensees include 5 physicians and 1 licensed acupuncturist.

Oregon Medical Board Actions, February-March 2026

The Oregon Medical Board published its action report summarizing regulatory activities between February 16, 2025, and March 15, 2026. The report covers Consent Agreements, Stipulated Orders, Emergency Suspensions, Final Orders, and other licensee actions. Three specific licensees are noted: Brigitte Diane Buehler, PA entered a non-disciplinary Consent Agreement for Re-Entry to Practice requiring 2,000 hours of supervised practice; Barbara Ayres Ball Trask, PA had a prior Consent Agreement terminated; and Sajad Zalzala, MD received a Notice of Proposed Disciplinary Action. The report indicates certain documents are available upon request through the Board's website or by contacting the Board directly.

Oregon Medical Board Actions, Jan 16 - Feb 15 2026

The Oregon Medical Board published its February 2026 Board Action Report covering actions from January 16 to February 15, 2026. The report documents multiple enforcement actions including Consent Agreements for Re-Entry to Practice, an Interim Stipulated Order for license inactivation pending investigation, and a Notice of Proposed Disciplinary Action. The Board maintains that interim actions are preliminary and do not constitute final disciplinary determinations.

Code of Virginia Administrative Process Act - 2025 Compilation

The Virginia General Assembly enacted the Administrative Process Act (Code of Virginia § 2.2-4000 et seq.), establishing the procedural framework for Virginia state agencies to adopt regulations and adjudicate cases. The Act codifies requirements for public participation in rulemaking, evidentiary hearings, hearing officer qualifications, and court review of agency decisions. The 2025 compilation includes guidance document provisions (§ 2.2-4002.1), fast-track rulemaking (§ 2.2-4012.1), and periodic review requirements (§ 2.2-4017).

License Suspension FAQ: Reinstatement Process for Virginia Healthcare Professionals

The Virginia Department of Health Professions published an FAQ explaining the mandatory license suspension process under Virginia Code § 54.1-2409 and the reinstatement process for healthcare professionals. Suspensions are triggered by felony convictions, license revocations/suspensions in other states, or surrenders in lieu of discipline in other states. The document outlines that reinstatement applicants must submit an application, cooperate with an investigation, and appear before the Board, which has 60 days to schedule a hearing after receiving a complete application.

Professional Medical Conduct Board Actions, 9,186 Records

The New York Office of Professional Medical Conduct publishes a dataset of 9,186 final disciplinary actions against medical professionals dating back to 1990. The data preview displays 50 recent entries including physician assistants, doctors of osteopathy, and medical doctors with effective dates ranging from February to March 2026. Actions include license numbers, license types (MD, DO, PA), and individual identifiers.

Two Men Charged With Fentanyl Manufacturing in NYC Building

DEA New York Division Special Agent in Charge Farhana Islam announced that two men have been charged with narcotics and firearms offenses for operating a fentanyl manufacturing plant in a residential building in New York City. The charges include narcotics manufacturing and distribution violations. This enforcement action was conducted in coordination with the Department of Justice.

Oregon Board of Pharmacy Disciplinary Actions, February 2026

The Oregon Board of Pharmacy issued disciplinary actions against seven licensees in February 2026, including pharmacists, pharmacy technicians, and pharmacy facilities. Affected parties include Mary Meng-Tai Lim (RPH-0008986), JAMS RX (W1-0004712), Corrina Wynn (CPT-0015898), Michael Sean Phelps (CPT-0009066), Lacey J Holsten (T-00320402), Collin Michael Hertzog (PI-0014916), and Navid Vahedi (RPH-0014571). Specific case numbers are listed, and public records requests may be submitted for additional information.

October 2025 Disciplinary Action Report, 5 Licensees

The Oregon Board of Pharmacy published its monthly disciplinary action report for October 2025, listing five licensees against whom the Board has issued enforcement actions. The report contains licensee names, license numbers, and associated case numbers. Specific violations and penalties are not disclosed in this report; the full Board Orders are available through online verification or public records request.

Oregon Board of Pharmacy September 2025 Disciplinary Actions

The Oregon Board of Pharmacy published its September 2025 disciplinary action report covering 09/01/2025 through 09/30/2025. The report documents 8 enforcement actions against pharmacy licensees including pharmacists, pharmacy technicians, and pharmacy facilities. Cases listed include OMNICARE OF RP-0001227, JAZMIN ARELY T-0031430, AMANDAH KYM CPT-0010391, AMY HUONG MAI RPH-0009430, SEBASTIAN RISKIN RPH-0009699, WILLEM MARAIS RPH-0010399, and others. Orders are available for public review via the OBOP online licensure verification system under Board Orders.

March 2026 Oregon Pharmacy Board Disciplinary Actions Report

The Oregon Board of Pharmacy issued disciplinary actions against multiple licensees during March 2026, including pharmacists, pharmacy technicians, and pharmacy facilities. Actions included licensees with case numbers ranging from 2020-0322 to 2026-0012. Some orders were issued as Oregon Board of Pharmacy v. proceedings, indicating formal disciplinary complaints. The report covers the period 03/01/2026 through 03/31/2026.

Oregon Pharmacy Board Disciplinary Actions, January 2026

The Oregon Board of Pharmacy published its January 2026 disciplinary report listing 8 licensees subject to executed orders. Actions involve pharmacies and individual pharmacists including Drug Mart Pharmacy, UsPharma Ltd Co, RARX II LLC, and multiple registered pharmacists. The board's orders are public records available through the OBOP online licensure verification system.

Observational Trial of Deep Learning Model for Head and Neck Cancer Prognosis

NIH registered NCT07532928, an observational study developing a dynamic deep learning model using multimodal patient data to assess prognostic risk and recommend individualized adjuvant treatment for locally advanced head and neck squamous cell carcinoma. The model aims to assist clinicians in precision therapy decisions. The study is observational with an estimated enrollment of 500 participants, registered April 16, 2026.

ML/AI Model Predicts Head and Neck Cancerous Lesion Risk

NIH registered ClinicalTrials.gov study NCT07532538, an observational multi-center trial to develop and validate a deep learning/AI-based clinical prediction model for head and neck cancerous lesion risk. The study targets hypopharyngeal cancer, laryngeal cancer, and general head and neck cancer. The trial is registered as an observational study without stated enrollment or completion dates.

Congenital Ptosis Surgery Visual Function and Psychological Conditions Prospective Cohort Study

NIH ClinicalTrials.gov registered NCT07534436, an observational prospective cohort study evaluating 6-month outcomes of Levator Resection combined with Fascial Sheath Suspension surgery in patients with congenital ptosis. The study will assess improvements in best-corrected visual acuity, stereopsis, and patient-reported quality of life through standardized ophthalmological examinations at baseline and 1, 3, and 6 months post-operation. Enrollment includes patients already scheduled for this combined surgical procedure as part of their regular medical care.

IPEX Observational Study on Pancreatic Exocrine Insufficiency in IPMN Patients

NIH registered the IPEX study (NCT07535125), a multicenter prospective observational cohort study evaluating pancreatic exocrine insufficiency (PEI) prevalence in patients with intraductal papillary mucinous neoplasms (IPMN) under surveillance. The study will assess whether PEI correlates with morphologic disease progression and whether it can serve as a functional marker complementary to imaging criteria in IPMN surveillance.

Guselkumab High-Dose vs Standard-Dose Study in Chinese Moderate-to-Severe Plaque Psoriasis

NIH registered a clinical trial (NCT07532486) on ClinicalTrials.gov evaluating the efficacy, safety, tolerability, and drug survival of guselkumab at high-dose and extended-interval regimens versus standard-dose in Chinese participants with moderate-to-severe plaque psoriasis. The interventional study compares two guselkumab dosing approaches. This is an administrative registration entry with no regulatory compliance obligations.

BOUGIE CAP Cohort Study, Esophageal Strictures

The NIH ClinicalTrials.gov registry has posted an observational cohort study (NCT07534800) evaluating the BougieCap™ device (Ovesco Endoscopy AG) for treating benign and short esophageal strictures. The study aims to assess the device's performance and short-term effectiveness on dysphagia. This is an informational registration entry for an ongoing clinical study.

Phase 4 Trial Comparing Symptom-Based vs. Full-Course Antibiotic Stop Rules in Children

NIH has registered a Phase 4 clinical trial (NCT07532941) at the Royal Children's Hospital evaluating whether oral antibiotics can be safely stopped when symptoms resolve in children who have completed IV antibiotic courses for cellulitis, UTI, LRTI, and lymphadenitis. The two-arm study compares symptom-triggered antibiotic cessation against traditional full-course completion. Participants complete daily symptom trackers with telehealth follow-up at symptom resolution, plus surveys at days 14, 28, and 180. The trial seeks to determine if abbreviated oral antibiotic courses are non-inferior to completing prescribed durations.

Piloting a Generative Artificial Intelligence Chatbot in a Mobile Weight Loss Program

NIH has registered a new clinical trial (NCT07534254) evaluating the feasibility of integrating a generative AI chatbot into a 12-week smartphone-based behavioral weight loss program for young adults. The study will compare standard program delivery (1-2 brief daily messages) against the same program enhanced with an AI chatbot offering additional behavior change support. Participants will be assessed on program feasibility, acceptability, engagement, and weight change outcomes.

Trial Comparing Ultrasound-guided vs Arthroscopic Guided PRF Injection for TMJ Disc Displacement

NIH registered a clinical trial (NCT07535073) comparing ultrasound-guided versus arthroscopic guided platelet rich fibrin injection for temporomandibular joint disc displacement. The trial will evaluate pain reduction, improvement of mandibular function, and patient-reported outcomes. No regulatory obligations or compliance requirements are created by this study registration.

ACOD1 Gene Expression as Sepsis Mortality Predictor

NIH has registered a new observational clinical study (NCT07533994) on ClinicalTrials.gov evaluating ACOD1 gene expression in peripheral blood mononuclear cells as a prognostic biomarker for predicting sepsis mortality. The single-center study will enroll septic ICU patients and correlate ACOD1 expression with clinical severity scores and in-hospital mortality outcomes.

Tpex Subsets in Negative Tumor Draining Lymph Nodes for Predicting Efficacy of PD-1 Inhibitors in Esophageal Squamous Cell Carcinoma

NIH registered an observational study (NCT07533357) examining Tpex subsets in negative tumor draining lymph nodes as predictors of PD-1 inhibitor efficacy in advanced or recurrent esophageal squamous cell carcinoma. The study aims to determine whether high proportions of precursor exhausted T cells correlate with longer overall survival and whether Tpex has better predictive efficacy for treatment response than PD-L1 CPS.

Preoperative Topical Lidocaine Versus Intravenous Fentanyl for Intubation Stress Reduction

NIH registered clinical trial NCT07533643 comparing preoperative topical lidocaine versus intravenous fentanyl for reducing stress response during endotracheal intubation under general anesthesia. The trial will evaluate hemodynamics after intubation using combined topical airway anesthesia (nebulized, mouth rinsing and gargling) against low-dose IV fentanyl. No compliance obligations are created by this trial registration.

Medical Digest Newsletter Subscription Page

The Alabama Board of Medical Examiners and Medical Licensure Commission maintains a Medical Digest newsletter for licensees containing disciplinary action lists and regulatory information. Licensees receive the digest automatically at their email address of record and may optionally subscribe to mail delivery. Non-licensees may request email subscriptions. The page archives past issues from 2022 through 2026 covering topics including license renewals, prescribing guidelines, CME requirements, and complaint procedures.

Alabama Medical Board Licensee Search Information

The Alabama Board of Medical Examiners provides information about its public licensee search tool, offering license verification including name, license number, status, issue/expiration dates, medical school, controlled substances certificates, collaborative practice information, and disciplinary actions. The search serves as primary source verification for credentialers and includes a downloadable daily-updated license roster CSV file. Confidential information including patient complaints, malpractice cases, investigations, full addresses, and birth dates is not provided.

Pharmacy Technician Employment Disqualification List 2026

The Missouri Board of Pharmacy published its 2026 Pharmacy Technician Employment Disqualification List, containing approximately 100 individuals who are prohibited from employment as pharmacy technicians in Missouri. The list includes names, license numbers, action dates, action taken, and location information. Pharmacies and employers should consult this list and the Conditional Registration List to verify authorization before hiring pharmacy technicians.

Missouri Pharmacy Technician License Suspensions Pursuant to Section 324.010 RSMo

The Missouri Board of Pharmacy has published a list of pharmacy technician licenses suspended pursuant to Section 324.010, RSMo. The document includes names, license numbers, cities, and effective suspension dates for numerous individuals. Pharmacy technicians, healthcare providers, and pharmacies should verify current license status through the MO BOP before employment or dispensing decisions.

Pharmacy Technician Conditional Registration List

The Missouri Board of Pharmacy publishes its Conditional Registration List for pharmacy technicians. This list identifies individuals eligible for employment as pharmacy technicians under conditions printed on their registration certificates. The list includes names, cities, and end dates for conditional employment status. Pharmacists and employers should check this list alongside the Employment Disqualification List to verify authorization to work.

29 Pharmacy Licenses Revoked Probationed Surrendered

The California Board of Pharmacy published disciplinary actions for 29 licensees (pharmacists and pharmacy technicians) for the period October 1 through December 31, 2025. Actions included 14 outright revocations with ended practice rights, 11 stayed revocations with probation terms ranging from 35 months to 5 years, 2 voluntary surrenders, 3 application denials, and 1 dismissal. Decisions were effective between October 15 and December 19, 2025.

41 Disciplinary Actions Against Pharmacy Professionals, July-September 2025

The California Board of Pharmacy published 41 disciplinary actions against pharmacy professionals for the period July 1 through September 30, 2025. Actions include 11 full revocations, 16 stayed revocations with probation periods ranging from one to five years, 5 voluntary surrenders, 2 application denials, 1 public reproval, and 1 withdrawn accusation. Decisions were effective between July 16 and September 24, 2025.

40 Pharmacy Licensees Disciplined, April-June 2025

The California Board of Pharmacy published disciplinary actions against 40 licensees for the period April 1 through June 30, 2025. Outcomes include license revocations (with some stayed and placed on probation), voluntary surrenders, and one withdrawn accusation. Decisions were effective between April 2 and June 27, 2025.

40+ Pharmacy Technician and Pharmacist License Revocations, Probations, and Surrenders, Q1 2026

The California Board of Pharmacy issued 40+ disciplinary decisions against licensed pharmacists and pharmacy technicians between January and March 2026. Outcomes include license revocations (with or without stayed revocation/probation), public reprovals, and voluntary surrenders. Cases span multiple cities across California including Los Angeles, Bakersfield, San Diego, and others.

Disciplinary Actions April-June 2026: Revocations, Probations, Surrenders

The California Board of Pharmacy published 15 disciplinary actions for Q2 2026 (April-June), affecting 13 personal licenses and 2 facility licenses. Decisions include absolute revocations, stayed revocations with probation, and voluntary surrenders. All decisions were effective April 1, 2026.

Brett Tyler Wahlgren M.D. Voluntary License Surrender

Dr. Brett Tyler Wahlgren, M.D./D.O. voluntarily surrendered his Alabama medical license (No. 43092) while under investigation by the Alabama State Board of Medical Examiners. The surrender, executed October 13, 2023, under Ala. Code § 34-24-361(g), constitutes a public record and will be reported to the National Practitioner Data Bank and Federation of State Medical Boards. The Board may summarily deny any reinstatement petition for two years, and reinstatement requires the physician to prove fitness to practice.

Dr Shakir Meghani Alabama Controlled Substances Certificate Reinstated With Conditions

The Alabama State Board of Medical Examiners issued an Amended Consent Order reinstating Dr. Shakir R. Meghani's controlled substances prescribing authority (Certificate No. ACSC.22917) with conditions. The physician's prescribing privileges had been restricted in October 2019 under a Consent Order. The reinstated authority covers Schedules II through V controlled substances and is contingent upon continued participation in a CPEP education plan, monthly reporting, adherence to preceptor oversight, and agreement to surrender the certificate upon any violation of the order.

Evann Herrell, DO Voluntary Surrender - Alabama Medical License and Controlled Substances Certificate

Evann Max Herrell, DO voluntarily surrendered their Alabama medical license (DO.1586) and Alabama Controlled Substances Certificate (ACSC.DO.1586) under Ala. Code § 34-24-361(g). The surrender, executed December 30, 2023, was made while under investigation by the Alabama State Board of Medical Examiners and includes all authority to prescribe Schedule II through V controlled substances. The surrender will be reported to the National Practitioner Data Bank and Federation of State Medical Boards.

Steven W. Powell, MD Voluntarily Surrenders Alabama Medical License

The Alabama State Board of Medical Examiners accepted the voluntary surrender of medical license MD.39044 from Steven Wayne Powell, M.D. The surrender was executed while Powell was under investigation by the Board and carries the same legal effect as revocation under Ala. Code § 34-24-361(g). Powell waived his right to a hearing and knowingly forfeited his right to practice medicine in Alabama.

Victor Jimenez Bonuel MD Voluntary Surrender and Temporary Suspension of Alabama Controlled Substances Certificate

The Alabama State Board of Medical Examiners accepted the voluntary surrender of Alabama Controlled Substances Certificate ACSC.38778 from Victor Jimenez Bonuel, M.D. and simultaneously issued an Order Temporarily Suspending the certificate. The physician was under investigation related to controlled substance prescribing. The surrender covers authority to order, manufacture, distribute, possess, dispense, administer, or prescribe all controlled substance schedules. The Board may summarily deny any reinstatement petition for two years from the effective date.

CMS Regulatory Comment Form - Regulations.gov

CMS is accepting public comments through Regulations.gov on a pending federal healthcare regulation. The comment period remains open for 32 days. Stakeholders may submit comments as individuals, organizations, or anonymously, with all submissions added to the public docket.

Medicaid CCBHC Services SPA Template Comment Form

CMS has opened a public comment period on a template for state Medicaid agencies to use when submitting State Plan Amendments (SPAs) to cover Certified Community Behavioral Health Clinic (CCBHC) services. Comments are being accepted through April 30.

Safety Alert: Maintenance of CO2 Laser and VersaPulse PowerSuite DW Systems by Boston Scientific

ANSM registered safety action R2609352 regarding Boston Scientific's CO2 laser systems and dual-wavelength VersaPulse PowerSuite systems. Healthcare facilities using these laser devices have received a direct correspondence from Boston Scientific dated 16/04/2026 containing safety information. ANSM directs users with questions to contact Boston Scientific directly.

Medtronic SynchroMed Implantable Pump Software Safety Alert for Health Establishments

ANSM has published a safety alert (Ref. R2610621) informing French healthcare establishments of a safety action taken by Medtronic Inc. regarding SynchroMed implantable pumps and associated software for the clinical programming tablet. Users have received a letter dated 16/04/2026 with details of the safety concern and recommended actions.

FH Ortho Biolox Delta Femoral Head Recall - ANSM Safety Alert R2610624

ANSM has recorded a lot withdrawal action by FH Ortho affecting Biolox Delta femoral heads used in hip prostheses. The safety action is registered as No. R2610624. Healthcare establishments that received the recall letter should contact FH Ortho directly with any questions.

Oklahoma Nursing Board July 2025 Disciplinary Actions

The Oklahoma Board of Nursing issued disciplinary actions against 13 licensees following its July 2025 Board meeting. Actions included suspensions with conditions, temporary suspensions pending hearings, and revocations ranging from two to five years. Affected licensees include registered nurses and licensed practical nurses holding single-state licenses under Oklahoma statutes.

Oklahoma Nursing Board Revocations and Suspensions, May 2025

The Oklahoma Board of Nursing Investigative Division published a list of license revocations, suspensions, and temporary suspensions following the May 2025 Board Meeting. Actions include revocations for two years with conditions, temporary suspensions pending Board hearings, and suspensions per statute. Legal bases include default from peer assistance program, dishonored payment instruments, and criminal sentencing.

Oklahoma Nursing Licenses Revoked, Suspended, Disciplined

Oklahoma Nursing Licenses Revoked, Suspended, Disciplined

Oklahoma Nursing License Suspensions and Revocations - March 2025 Board Actions

The Oklahoma Board of Nursing's Nursing Investigative Division published March 2025 Board Actions listing disciplinary measures against nursing licensees including suspensions and revocations. Named individuals include registered nurses Amanda Urisa, Kimberly Jo Vessells, Misty Michelle Cox, Elizabeth Woodland Davis, and others with licenses revoked for two years with conditions or suspended per statute. Actions were taken under Oklahoma Statutes 59 OS § 567.7 F, 567.8 N, and 567.17 I.

Oklahoma Nursing Board July 2025 Disciplinary Actions

Oklahoma Board of Nursing published its July 2025 disciplinary actions, reporting 13 license suspensions and revocations against registered nurses (RNs) and licensed practical nurses (LPNs). Actions range from temporary suspensions pending Board hearings to permanent revocations spanning two to five years with conditions for reinstatement.

Metabolic Disorders Accelerate cACLD Progression in 4,307 Adults

ClinicalTrials.gov registered NIH observational cohort study NCT07534046 investigating how metabolic disorders (obesity, diabetes, high cholesterol) influence progression of compensated advanced chronic liver disease (cACLD) in approximately 4,307 adults. The multicenter study across six centers in China will follow participants every 3-6 months for up to 5 years collecting clinical assessments, MRI elastography imaging, metabolic indicators, and biological samples. No experimental treatments are administered; participants receive standard care.

Testing Conversational Agents as a Digital Companion for Autistic Adults

NIH has registered a new clinical trial (NCT07533331) testing an AI-powered digital companion app using conversational-relational agents to provide self-directed goal coaching for autistic young adults ages 18-35. The single-arm study will evaluate whether the technology platform improves mental health, social connection, and life outcomes over a 6-month intervention period. The estimated primary completion date is April 16, 2026.

Randomized Controlled Trial of Dry Needling for Provoked Vestibulodynia

NIH registered a multicenter randomized controlled trial (NCT07534345) on ClinicalTrials.gov evaluating dry needling efficacy for provoked vestibulodynia (PVD), a chronic vulvar pain condition affecting up to 16% of women. The study will randomize 300 women to receive either real or sham dry needling over 8 weekly sessions, with outcomes assessed at baseline, post-treatment, and 6-month follow-up.

Impella 5.5 Echocardiographic Study on Heart Failure

The NIH has registered a prospective observational clinical study (NCT07534462) on ClinicalTrials.gov evaluating the effects of the Impella 5.5 mechanical circulatory support device on biventricular function in adult patients with end-stage heart failure. The study will assess echocardiographic parameters including left and right ventricular global longitudinal strain and myocardial work at baseline, immediately after device initiation, and during 7-14 day follow-up. This observational study involves collection of echocardiographic imaging and clinical data from patients requiring temporary mechanical circulatory support.

Post-Transplant Dental Cleaning to Prevent Chronic Graft-Versus-Host Disease

NIH's ClinicalTrials.gov registered a new clinical trial (NCT07535008) evaluating whether post-transplant dental cleaning can prevent chronic graft-versus-host disease (GVHD) in patients undergoing allogeneic hematopoietic cell transplant. The trial will study dental cleaning and dental plaque sampling as interventions against chronic and acute GVHD in patients with hematopoietic and lymphatic system neoplasms.

Influence of Clear Aligner Marginal Termination Design on Subgingival Periodontal Microbiota: Split-Mouth Study

NIH registered a clinical trial (NCT07533058) examining whether supragingival versus juxtagingival clear aligner edge designs affect subgingival periodontal microbiota in orthodontic patients. The split-mouth study will compare aligner edge designs covering 2mm of gum tissue versus those following the gumline exactly over 8 weeks of wear. The trial will enroll participants undergoing finishing phase orthodontic treatment to assess disease-associated bacteria levels.

NCT07533409 - Tactile and Pain Sensory Thresholds and Hand Grip Strength in Children

NIH registered an observational clinical trial (NCT07533409) on ClinicalTrials.gov comparing fingertip tactile sensation, hand and finger grip strength, and hand pain thresholds in children diagnosed with specific learning disorder with impairment in written expression versus healthy controls. The study is classified as observational with treatment outcome interventions.

VR Upper Limb Rehabilitation for Chronic Stroke Randomized Trial

NIH/NLM registered a randomized controlled trial (NCT07534124) evaluating non-immersive virtual reality rehabilitation (MindMotion GO) versus conventional occupational therapy for upper limb motor function in chronic stroke patients. The 8-week study with 3-month follow-up will assess motor function, daily living performance, quality of life, and neuroplastic changes via EEG. Enrollment and results will be posted to ClinicalTrials.gov.

Structured Yoga Program Improves Balance in Children with Down Syndrome: Clinical Trial NCT07534085

NIH's ClinicalTrials.gov registry has posted a new study (NCT07534085) evaluating a 12-week adaptive yoga program on balance and functional performance in 15 children aged 7-12 with Down syndrome. The single-arm intervention includes yoga exercises, breathing techniques, and relaxation practices, with balance assessed using sensor-based digital systems. The study's primary completion date is April 16, 2026.

FDA Regulatory Burdens for Mid-Sized Pharma Under 100% Drug Tariffs

Maynard Nexsen published analysis on April 16, 2026 examining how mid-sized branded pharmaceutical companies and specialty biotech face significant FDA regulatory obligations when attempting to relocate manufacturing to mitigate the 100% drug tariffs announced by President Trump on April 2, 2026. The article explains that moving drug substance, drug product, fill-finish, or packaging operations to new facilities triggers FDA postapproval change requirements, including Prior Approval Supplements that can delay commercial shipments by 6-12+ months.

Hospices Face Increased Scrutiny Under New CMS Scoring

CMS has proposed a new Service and Spending Variation Index (SSVI) scoring system for hospice providers to be implemented in fiscal year 2027. The system will track metrics including non-hospice spending, length of stay, live discharge return rates, and average minutes per routine home care day. Facility SSVI scores will be publicly posted on the CMS Hospice Center webpage, with high scores triggering increased oversight, additional reviews, and potential license revocations.

EMA Q2 2026 Pilot Programme for Breakthrough Medical Devices and IVDs

The European Medicines Agency (EMA) is launching a pilot programme in Q2 2026 to provide expert panel advice for developers of breakthrough medical devices and in vitro diagnostics (IVDs). Manufacturers may request expert panel opinions on whether their products meet breakthrough criteria (novelty and positive clinical impact) and, if confirmed, obtain advice on clinical development strategies and appropriate pre-clinical or clinical data. The pilot builds on MDCG 2025-9 guidance and will inform the European Commission's proposed revisions to the MDR and IVDR.

DOJ's Bulk Sensitive Data Transfer Rule: Key Insights for Health Care Compliance

Epstein Becker Green analyzes the U.S. Department of Justice's Bulk Sensitive Data (BSD) Transfer Rule, which imposes compliance obligations on healthcare and life sciences organizations that transfer or provide access to sensitive data, including genomic information. The rule applies when data on as few as 100 individuals is shared, catching many organizations unprepared. The BSD Transfer Rule creates obligations that extend beyond HIPAA, applying even to de-identified or anonymized data, and covers any access by foreign vendors, board members, or investors—not only formal data-sharing agreements.

New York Requires Employers to Stock Opioid Antagonists

New York enacted NY Labor Law § 27-f, requiring private employers already mandated by OSHA standards to maintain first aid kits to also stock opioid antagonists (naloxone). Governor Hochul signed the amended bill on February 13, 2026, with the law taking effect December 13, 2026. The NY State Department of Labor must issue regulations addressing workplace training and required quantities.

HHS OIG Provides Succession Planning Roadmap for ASCs

HHS OIG issued Advisory Opinion 26-04 concluding it would not impose administrative sanctions under the Anti-Kickback Statute for a physician's proposed transfer of ownership interests in an ambulatory surgery center (ASC) as part of estate and succession planning. Despite the arrangement's failure to satisfy every element of the ASC investment safe harbor, the OIG determined the proposal presented sufficiently low fraud and abuse risk due to fair market value pricing, proportional profit distributions, and absence of referral-related conditions.

FDA Defaults to Single Pivotal Trial for Drug Approvals

FDA Commissioner Martin Makary and CBER Director Vinay Prasad announced FDA's new default standard requiring only one pivotal trial for drug approvals instead of two. The agency also released draft guidance establishing a Plausible Mechanism Framework for individualized gene-editing and RNA-based therapies targeting rare genetic conditions. Drug sponsors should note potential increased post-market data collection obligations under the new framework.

Nevada State Board of Nursing Disciplinary Actions October 16 Through December 8 2025

Nevada State Board of Nursing published its quarterly disciplinary and licensure actions covering October 16 through December 8, 2025. The document summarizes multiple enforcement cases against registered nurses, advanced practice nurses, certified nursing assistants, and CNA applicants. Violations cited include NRS 632.347 (1)(g) unprofessional conduct, medication errors, unauthorized drug administration, scope of practice violations, diversion of supplies, and fraud in license procurement. Actions include agreements for reprimand, probation, practice restrictions, voluntary license surrender, application denial, and revocation orders.

Nevada State Board of Nursing Disciplinary Actions February-April 2025

The Nevada State Board of Nursing published disciplinary and licensure actions for the period February 3, 2025 through April 10, 2025. The document records multiple enforcement outcomes including license revocations, reprimands with continuing education requirements, renewal application denials, and voluntary surrenders. Violations cited include NRS 632.347 (unprofessional conduct, controlled substances, criminal convictions, action in another state) and NAC 632.890 (customary standards of practice, failure to collaborate with healthcare team, threats of violence).

NV Nursing Board 13 Disciplinary Actions Jul-Sep 2024

The Nevada State Board of Nursing issued 13 disciplinary actions against nurses and nursing assistants for the period July 31 through September 30, 2024. Actions included agreements for reprimand with continuing education, probation, license revocation, and voluntary surrender of licensure. Violations cited included unprofessional conduct, controlled substance/alcohol issues, patient privacy breaches, and failure to comply with Board orders.

NV BON Disciplinary Actions: Agreements, Fines, Probations, Suspensions

The Nevada State Board of Nursing issued disciplinary orders against multiple nurses including RNs, APRNs, LPNs, and CNAs for violations including unprofessional conduct, controlled substance violations, practicing without proper licensure, and failing to meet standards of practice. Actions include agreements, reprimands, fines ranging from $100 to several hundred dollars, probationary terms, required continuing education, and license denial.

Nevada Nursing Board Probations, Reprimands, License Denials, Surrenders

The Nevada State Board of Nursing published its disciplinary and licensure actions for the period December 8, 2025 through February 4, 2026. Actions taken include agreements for probation (terms of 18 months to 5 years), reprimands with required continuing education, CNA renewal application denials, and voluntary certificate surrenders. Violations cited include NRS 632.347 (unprofessional conduct), NAC 632.890 (various practice standards including inaccurate recording, falsifying records, practice beyond scope, customary standards of practice, and violation of state/federal nursing law), and NRS 632.415.

Public Comment Guidelines for Montana Nursing Board Meetings

The Montana Department of Labor & Industry Business Standards Division implemented public comment guidelines for professional and occupational licensing board meetings, effective August 1, 2022. The guidelines establish a consistent approach for public members to comment during board meetings, including procedures for submitting written comments at least seven days prior to scheduled meetings. The board may limit or close public comment periods and cannot act on items not on the current agenda.

Montana Board of Nursing Public Comment Guidelines for Meetings

The Montana Department of Labor & Industry's Business Standards Division implemented public comment guidelines for professional and occupational licensing board meetings effective August 1, 2022. The changes establish consistent procedures for public participation including non-agenda public comment periods and agenda item-specific comment periods, with written comments required seven days prior to scheduled meetings.

Public Comment Guidelines for Montana Professional Licensing Boards

The Montana Department of Labor & Industry's Business Standards Division implemented public comment guidelines for professional and occupational licensing board meetings effective August 1, 2022. The guidelines establish procedures for public comment during meetings, including requirements for written submissions to be made at least seven days before scheduled board meetings, with specifications for including name, organization representation, and agenda item references. These changes apply to all professional and occupational licensing boards under the Montana Department of Labor & Industry.

Public Comment Guidelines for Professional Licensing Board Meetings

The Montana Department of Labor & Industry Business Standards Division implemented public comment guidelines for professional and occupational licensing board meetings effective August 1, 2022. The guidelines standardize how public members may comment during board meetings, establish submission deadlines, and define procedural rules for comment periods. Nursing professionals, licensees, and members of the public seeking to participate in board meetings are affected by these procedures.

Public Comment Guidelines for Montana Board of Nursing Meetings

The Montana Department of Labor & Industry's Business Standards Division implemented public comment guidelines for professional and occupational licensing board meetings, including the Montana Board of Nursing, effective August 1, 2022. The guidelines establish procedures for public comment on non-agenda items and agenda items during board meetings, with written comments due seven days prior to scheduled meetings.

January 2026 VN Accusations, Citations, and Disciplinary Decisions

CA BVNPT published its monthly enforcement compilation for January 2026, documenting 17 accusations filed against VN and PT licensees, 38 administrative citations issued, 6 statements of issues filed, and 18 final disciplinary decisions and orders. All listed licensees hold either Vocational Nurse (VN) or Psychiatric Technician (PT) credentials issued by the California board.

December 2025 CA VN Accusations, Citations, Decisions

CA BVNPT published December 2025 monthly enforcement summary listing 11 accusations filed against vocational nurses (License types VN), 25 citations issued to VN and PT licensees, and 7 decisions and orders filed including 1 entity. The document records administrative enforcement actions for the month of December 2025.

California Vocational Nursing Disciplinary Actions, November 2025

The California Board of Vocational Nursing and Psychiatric Technicians published November 2025 disciplinary records covering 29 accusation filings against vocational nurses, 29 citation issuances, and 6 decisions and orders. The records include respondent names, license numbers, and filing dates from November 4-25, 2025.

California Vocational Nursing Disciplinary Actions October 2025

The California Board of Vocational Nursing and Psychiatric Technicians published its October 2025 disciplinary actions report documenting accusations, citations, and final decisions against licensees. The report lists 16 accusations filed against vocational nurses, 2 statements of issues filed, 33 citations issued to licensees including VNs and PTs, and 16 final decisions and orders issued against vocational nurses and entities.

February 2026 Accusations Citations and Decisions List

The California Board of Vocational Nursing and Psychiatric Technicians published its February 2026 enforcement summary documenting accusations filed, citations issued, and final decisions against licensees. The document records 12 accusations filed against vocational nurses, psychiatric technicians, and one registered nurse; 30 citations issued; and 6 decisions and orders finalizing prior enforcement actions.

Real World MAIA UK Outcomes - Observational Myeloma Trial, DRd Therapy

The NIH registered observational study NCT07532473 on ClinicalTrials.gov to assess real-world use and clinical outcomes of triplet therapy daratumumab, lenalidomide, and dexamethasone (DRd) in transplant-ineligible patients with untreated myeloma in the United Kingdom. The observational study will describe treatment patterns and associated clinical outcomes outside of clinical trial settings.

Sacral Fracture Fixation Trial Compares Open, Minimally Invasive Surgical Approaches

NIH's ClinicalTrials.gov has registered observational study NCT07534579 comparing open versus minimally invasive lumbopelvic fixation for unstable sacral fractures in adults. The retrospective study will review medical records and imaging of patients treated between January 2016 and December 2024 to evaluate physical function using the Majeed Pelvic Score, bone healing, surgical complications including wound infections and hardware failures, and clinical nerve function recovery.

Phase 1 Solid Tumor Trial of BMS-986504 Plus Standard-of-Care Therapy

NIH's ClinicalTrials.gov registered a Phase 1 clinical trial (NCT07532902) evaluating BMS-986504 in combination with standard-of-care anticancer therapies for patients with metastatic/advanced unresectable MTAP-deleted solid tumor cancers. The study will enroll participants with diffuse pleural mesothelioma, gastroesophageal carcinoma, and urothelial carcinoma. This is a routine clinical trial registration providing public access to study design and eligibility criteria.

Nurses' Knowledge of Initiating Mechanical Ventilation in ICUs (NCT07534202)

NIH ClinicalTrials.gov registered an observational study (NCT07534202) assessing intensive care unit nurses' knowledge regarding initiation of mechanical ventilation and associated nursing procedures in hospitals in southern Iraq. The study is categorized as observational with no interventional component.

Skin Acceptability Test for GINPI in Female Volunteers

NIH ClinicalTrials.gov registered Study NCT07533461, a Phase 4 clinical trial evaluating skin acceptability of the cosmetic product GINPI in healthy female adult volunteers under gynecological control. The study assesses organoleptic characteristics, subjective efficacy, and monitors for unexpected adverse events over a twice-daily application regimen for 54 participants.

BREATHE III Brazilian Registry of Heart Failure

NIH registered BREATHE III, a prospective multicenter observational registry on ClinicalTrials.gov studying acute heart failure patients in Brazil. The 12-month follow-up study will assess patient characteristics, treatment patterns, guideline-directed medical therapy adherence, time to treatment optimization, and clinical outcomes including barriers to implementation and regional variations in care.

Berry Mango Leaves Extract for Acute Rhinosinusitis Phase I Trial, 10 Subjects

ClinicalTrials.gov registered a Phase I controlled clinical trial (NCT07534280) studying the safety and efficacy of Berry leaves and Mango leaves herbal tea mixture for management of acute rhinosinusitis in adults. Ten subjects aged 18-70 will be enrolled from Minia University ENT outpatient clinic and followed for one month with telephone assessments at Days 0, 3, 7, 10, and 28.

Functional Outcomes and Control Using Synchron BCI - Australia (FOCUS-AUS)

NIH has registered a clinical trial on ClinicalTrials.gov for Synchron's brain-computer interface (BCI) device, known as the Stentrode. The FOCUS-AUS study will evaluate functional outcomes in patients with motor neuron disease and paralysis at Australian trial sites. The study has an anticipated completion date of April 16, 2026.

Radiographic Head and Neck Positional Changes in Response to Low-Powered Prismatic Lenses

NIH's ClinicalTrials.gov has registered a new observational study (NCT07532642) investigating short-term modifications in head and neck positioning through use of low-powered prismatic lenses in patients with Postural Deficiency Syndrome. The matched-pair study will evaluate patients using low-dose biplanar radiography before treatment and 15 minutes after lens application.

VAP-Measured Lipid Subfractions and In-Stent Restenosis After PCI (NCT07533656)

NIH registered multicenter observational study NCT07533656 investigating association between VAP-measured lipid/lipoprotein subfractions and coronary in-stent restenosis after PCI. Includes retrospective cross-sectional component (patients with prior PCI undergoing repeat angiography) and prospective follow-up component (patients undergoing index PCI). No additional blood draws required; serum samples from routine clinical collection used for VAP testing. Target enrollment: 140 participants. Conditions: In-Stent Restenosis, Coronary Artery Disease. No intervention.

CMS PRA Notice: Religious Nonmedical Health Care Institutions Conditions of Participation

CMS has published a 30-day notice under the Paperwork Reduction Act announcing an opportunity for public comment on an existing information collection for Religious Nonmedical Health Care Institutions (RNHCIs) Conditions of Participation. The notice covers compliance with health and safety requirements under Title 42 CFR Section 403, Subpart G. Comments on the burden estimate are due to the OMB desk officer by May 18, 2026.

Medicaid CCBHC Services State Plan Amendment Coverage Template PRA Notice

CMS published a Paperwork Reduction Act notice seeking public comments on the Medicaid Certified Community Behavioral Health Clinic (CCBHC) Services State Plan Amendment Coverage Template (CMS-10398 #45). The notice invites comments on burden estimates, necessity, utility, accuracy, and collection methods for this information collection request under OMB control number 0938-1148. Comments must be submitted by April 30, 2026.

Medicare Hospital IPPS FY 2027 Rates Proposed Rule Correction

CMS corrects a typographical error in the Medicare Hospital IPPS FY 2027 proposed rule published April 14, 2026. The correction changes the public comment deadline from incorrectly stated April 10, 2026 to the correct date of June 9, 2026.

Early Alert: Medical Action Industries Halyard Kit Recall - Angiographic Syringe Risk

FDA issued an early alert regarding Medical Action Industries convenience kits containing Medline Namic RA syringes subject to a Class I recall. The syringe rotating adaptor on affected devices may unwind during use, resulting in loose connections or full disconnection, with potential for biohazard exposure, blood loss, infection, air embolism, serious injury, or death. As of March 13, four serious injuries have been reported with no deaths. Affected parties must identify, segregate, and quarantine affected product and apply warning labels.

AI Thai Food App and CGM Monitoring Pilot Study for Type 2 Diabetes

NIH's ClinicalTrials.gov has registered NCT07533604, an 8-week randomized controlled pilot study evaluating an AI-powered Thai food analysis application (SnapD) combined with continuous glucose monitoring (CGM) for glycemic control in 45 patients with Type 2 Diabetes and overweight/obesity. The study has three arms: SnapD alone, SnapD with CGM, or standard diabetes self-management education. Participants will be monitored over 8 weeks with HbA1c as the primary endpoint.

Phase 1 KSD-101 Trial for EBV-Associated Hematological Malignancies

NIH ClinicalTrials.gov registered a Phase 1 study (NCT07532746) evaluating KSD-101 for relapsed or refractory EBV-associated hematological malignancies. The single-arm trial will assess safety, tolerability, preliminary efficacy, immune response, and quality of life in participants treated with KSD-101.

Multicentre Retrospective Cohort Study of Palliative Care Pathways in Patients Who Died From Sarcoma

NIH ClinicalTrials.gov registered multicentre retrospective observational study NCT07532668 examining palliative care pathways in adult patients who died from sarcoma. The study aims to describe how sarcoma patients who died were followed by palliative care teams. No regulatory obligations or compliance requirements are imposed by this study registration.

MINIMALLY INVASIVE SURGERY FOR GRADE III HEMORRHOIDS - Observational Study NCT07534761

NIH ClinicalTrials.gov registered a new observational study (NCT07534761) evaluating minimally invasive surgery (MIS) for Grade III hemorrhoids using a closed excisional hemorrhoidectomy technique. The IDEAL Phase 2a study aims to assess reproducibility and technical feasibility of MIS in anal surgery with approximately 50 participants.

Short Fiber vs Injectable Resin Composite in Class I Restorations

NIH ClinicalTrials.gov registered a Phase 4 clinical trial (NCT07535086) comparing short fiber reinforced flowable bulk fill resin composite to conventional injectable flowable resin composite for restoring Class I carious molar cavities. The trial will evaluate clinical performance of these dental restoration materials. Estimated study completion date is April 16, 2026.

Phase 2 Clinical Trial Evaluating HSK55718 for Postoperative Pain in Abdominal Surgery

NIH registered a Phase 2 clinical trial (NCT07533786) evaluating the efficacy and safety of investigational drug HSK55718 for postoperative pain treatment. The multi-center, randomized, double-blind, placebo/active-controlled study plans to enroll 200 subjects undergoing abdominal surgery under general anesthesia, comparing three dose levels of HSK55718 against morphine and placebo.

Comparing Medial and Lateral Dissection Approaches to the Recurrent Laryngeal Nerve During a Thyroidectomy

NIH registered a new interventional clinical trial (NCT07532889) comparing medial versus lateral dissection approaches to the recurrent laryngeal nerve during thyroidectomy. The randomized study will evaluate length of hospital stay, surgical adverse events, and post-operative vocal cord function. Participants scheduled for thyroidectomy will be enrolled after informed consent.

Potassium Channel Study in Chronic Cocaine Users

NIH registered a clinical trial (NCT07532460) on ClinicalTrials.gov investigating the role of potassium channels in working memory impairments among chronic cocaine users. The study will test 4-aminopyridine (4-AP) versus placebo as an intervention for cognitive impairments associated with cocaine use disorder. The trial is registered with an estimated start date of April 16, 2026.

Gas6 and Soluble MerTK Periodontal Biomarkers Study

NIH registered an observational clinical study (NCT07535177) investigating Gas6 and soluble MerTK biomarker levels in gingival crevicular fluid and serum samples across three groups: 30 patients with stage III grade B periodontitis, 30 with gingivitis, and 30 periodontally healthy individuals. The study will measure clinical periodontal parameters including probing depth, clinical attachment level, bleeding on probing, gingival index, and plaque index. Biomarker levels will be determined using enzyme-linked immunosorbent assay with non-parametric statistical analysis.

JZP3507 (ONC206) Phase 2 Trial for Recurrent Grade 2 or 3 Meningioma

NIH registered a Phase 2 clinical trial (NCT07533942) evaluating JZP3507 (ONC206) in patients with recurrent Grade 2 or 3 meningioma who have failed prior therapy. The single-arm study will administer oral JZP3507 and evaluate antitumor activity and safety. The trial is listed on ClinicalTrials.gov with an anticipated start date of April 16, 2026.

FCA Focus on Waste, Fraud, Data Analytics, Medicare Advantage

FCA Focus on Waste, Fraud, Data Analytics, Medicare Advantage

Sixth Circuit Holds ERISA Preempts Tennessee Pharmacy Anti-Steering Laws

In McKee Foods Corp. v. BFP Inc. (6th Cir., Apr. 7, 2026), the Sixth Circuit affirmed that ERISA preempts two Tennessee laws regulating pharmacy benefit managers (PBMs). The court held that the state's any-willing-provider provisions and incentive provisions, which aimed to prevent PBMs from steering patients to affiliated pharmacies, constituted impermissible interference with ERISA plan design and administration.

Notice of Approval of Product Under Voucher: Rare Pediatric Disease Priority Review Voucher; MRESVIA (Respiratory Syncytial Virus Vaccine)

FDA announces approval of MRESVIA (Respiratory Syncytial Virus Vaccine) and issuance of a Rare Pediatric Disease Priority Review Voucher under the voucher program established by the FDA Modernization Act of 2012. The approval was granted under Docket No. FDA-2026-N-3466 and published in 91 FR 20471 on April 16, 2026. This notice documents the completion of the regulatory review and voucher issuance for the vaccine product targeting RSV in pediatric populations.

Pharmacy Compounding Advisory Committee Meeting and Bulk Drug Substances Public Comment Request

The FDA announces a Pharmacy Compounding Advisory Committee meeting scheduled for July 23-24, 2026, and establishes a public docket (FDA-2025-N-6895) to receive comments on bulk drug substances nominated for inclusion on the Section 503A Bulk Drug Substances List. The agency seeks input from stakeholders on whether these nominated substances should be approved for use in pharmacy compounding.

AREXVY RSV Vaccine Approved for Rare Pediatric Disease Priority Review Voucher

The FDA granted a Rare Pediatric Disease Priority Review Voucher to AREXVY (Respiratory Syncytial Virus Vaccine, Adjuvanted) under Docket No. FDA-2026-N-3446. The voucher, published at 91 FR 20460, was awarded upon approval of the vaccine product.AREAS XVY is manufactured by GSK and is indicated for active immunization against RSV disease in adults 60 years and older, and in infants through maternal immunization.

MNEXSPIKE COVID-19 Vaccine Rare Pediatric Disease Priority Review Voucher Approval Notice

FDA issued a Notice announcing approval of MNEXSPIKE, an mRNA COVID-19 vaccine, under the Rare Pediatric Disease Priority Review Voucher program. The voucher program incentivizes development of treatments for rare pediatric diseases by providing priority review vouchers that can be used for future FDA review requests. Docket No. FDA-2026-N-3447.

MRESVIA RSV Vaccine Approval Under Material Threat Medical Countermeasure Priority Review Voucher

FDA approved MRESVIA (Respiratory Syncytial Virus Vaccine) using a Material Threat Medical Countermeasure Priority Review Voucher. The approval was announced via Federal Register Notice (Docket No. FDA-2026-N-3500, 91 FR 20467) on April 16, 2026. This action grants market authorization for the RSV vaccine, which was reviewed under an expedited pathway designed to encourage development of medical countermeasures addressing material public health threats.

Jessica de Mounteney Appointed First Parliamentary Counsel

Jessica de Mounteney has been appointed as the new First Parliamentary Counsel and Permanent Secretary of the Government in Parliament Group at the Cabinet Office, effective end of April 2024. She succeeds Dame Elizabeth Gardiner, who is departing after over 32 years of dedicated service. The appointment was made by the Prime Minister upon the recommendation of the Leader of the House of Lords. This is a routine administrative appointment to a senior civil service position within the UK's legislative drafting function.

Common Legislative Solutions: Guide to Tackling Recurring Policy Issues in Legislation

The Office of the Parliamentary Counsel has published updated guidance titled 'Common Legislative Solutions' to help government officials address recurring policy issues through commonly adopted legislative approaches. The guidance, produced with input from UK legislative drafting offices, identifies common policy problems and analyses possible legislative solutions. The document was last updated on 23 December 2025 with a new version of the guide.

Legislative Drafting: A Fictional Example

The Office of the Parliamentary Counsel published a fictional example illustrating its legislative drafting practice. The document shows how drafters translate government policy into legal language and subject policy to rigorous analysis to ensure provisions achieve their aims coherently. The example includes drafting instructions, an initial clause attempt, and a covering note demonstrating the iterative process between drafter and department.

Hungarian ICU Transfusion Practices Survey

NIH ClinicalTrials.gov registered observational study NCT07532772, a Hungarian nationwide survey assessing transfusion practices in intensive care units. The study will evaluate how physiological parameters recommended as transfusion triggers are used in daily clinical practice across Hungarian hospitals. No regulatory obligations or compliance requirements are imposed by this registration.

Fecal Microbiome Signature of Multi-Strain Probiotics Supplementation in Pediatric IBD

The NIH has registered a clinical trial (NCT07533890) to study fecal microbiome and metabolic profiles in children and adolescents with inflammatory bowel disease upon multi-strain probiotic supplementation. The study will enroll participants and begin interventions on April 16, 2026.

Leaf Expander vs Hyrax for Molar Distalization

NIH ClinicalTrials.gov registered a randomized controlled trial comparing skeletally anchored modified Leaf Expander versus conventional Hyrax Expander for maxillary molar distalization in 30 patients aged 15-18 years. The three-year study will evaluate skeletal, dental, and arch dimensional changes using lateral cephalometric radiographs and digital dental models.

Ga-68 PSMA PET/CT vs mpMRI in Cognitive Prostate Biopsy (NCT07533344)

The NIH ClinicalTrials.gov registry has registered observational study NCT07533344, an NCI-affiliated trial conducted by Stanford University comparing Ga-68 PSMA PET/CT imaging with multiparametric MRI (mpMRI) in cognitive prostate biopsy for prostate cancer diagnosis. The single-arm study will enroll approximately 100 participants and is estimated to begin enrollment on April 16, 2026.

MPXV Viral Clearance, Transmission Dynamics, and Vaccine Effectiveness Study in Guinea

NIH's ClinicalTrials.gov registered an observational study (NCT07534267) in Guinea, West Africa examining Monkeypox virus (MPXV) elimination kinetics from infected individuals, transmission dynamics between cases and contacts, and effectiveness of the MVA-BN vaccine against MPXV infection and Mpox disease. The study has three components: MOVIE-West Africa, TRACE-West Africa, and VE-West Africa.

DEA Addresses Drug Threats, Pharmacy Crime at Diversion Summit

DEA Assistant Administrator Cheri Oz addressed emerging drug threats, pharmacy crime, and prescription drug misuse at the National Association of Drug Diversion Investigators Rx Diversion Summit in Covington, KY. The remarks targeted over 300 pharmacists, investigators, and hospital leaders on controlled substance enforcement priorities.

Single-dose 7.2mg Semaglutide (Wegovy) Pen Approved for Adult Obesity

The MHRA approved a new single-dose 7.2mg semaglutide (Wegovy) pen for adult patients with obesity (BMI ≥30kg/m²). The approval consolidates the maximum weekly dose into one injection rather than three separate 2.4mg doses. Starting dose is 0.25mg weekly, gradually increasing every four weeks as prescribed. The agency will continue monitoring safety and effectiveness.

Synthetic CAR-T Cells for Treating IL13Ra2 Positive Human and Canine Tumors

The European Patent Office published patent application EP4021464A1 (A1 kind, April 8, 2026) for synthetic CAR-T cells targeting IL13Ra2 positive tumors in humans and canines. Applicant is The Trustees of The University of Pennsylvania. Inventors include O'ROURKE, Donald M., YIN, Yibo, JOHNSON, Laura, BINDER, Zev, and THOKALA, Radhika. The patent covers compositions and methods for treating IL13Ra2-positive tumors using synthetic chimeric antigen receptor T-cells.

Gene Therapy for Alzheimer's Disease - Brigham and Women's Hospital EP3976637

The European Patent Office published patent application EP3976637A1, filed by The Brigham and Women's Hospital, Inc. and The General Hospital Corporation, covering a gene therapy approach for treating Alzheimer's disease. The invention, developed by inventors Shen Jie and Kelleher III Raymond J., is classified under C12N 15/86 and related protein classification C07K 14/47. The patent is designated across all EU member states including AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, and TR.

Determining Structured Medical Findings in a Medical Report and Adjusting a Medical Report

The EPO published patent application EP4553842A1 by Koninklijke Philips N.V. titled 'Determining Structured Medical Findings in a Medical Report and Adjusting a Medical Report.' The invention covers methods for extracting structured findings from medical reports and adjusting medical report content. The patent is classified under G16H (Health Informatics) and designates 36 European countries including Germany, France, and the United Kingdom.

Dexcom EP4318489A2 Patent, Continuous Glucose Monitoring App Compatibility Check

The European Patent Office published patent application EP4318489A2 for Dexcom, Inc. covering a system and method for verifying compatibility of continuous glucose monitoring (CGM) applications. The patent application includes claims related to wireless communication protocols (H04W 4/20), healthcare data management systems (G16H 40/40), and software update mechanisms (G06F 8/65) for medical device applications. The patent is designated across 31 EPO member states including Germany, France, Italy, Spain, and the United Kingdom.

Governor Stein Recognizes Black Maternal Health Week, Highlights Maternal Health Disparities

Governor Josh Stein joined Senator Natalie Murdock and the North Carolina Legislative Black Caucus to recognize Black Maternal Health Week and raise awareness of racial disparities in maternal health outcomes. According to NCDHHS, Black women in North Carolina are nearly twice as likely as white women to die from pregnancy complications, with 57% of pregnancy-related deaths occurring during pregnancy or within six weeks postpartum and nearly 80% deemed preventable. The Governor highlighted budget investments including $319 million for Medicaid and $213 million through the Rural Health Transformation Program to improve maternal care access.

Letter on ACMD Work Programme 2026

The Advisory Council on the Misuse of Drugs (ACMD) published its work programme for 2026, outlining planned advisory activities and ongoing ministerial commissions. The letter from the ACMD Chair to the Minister for Policing and Crime details both requested advice and self-initiated work the council will undertake during the year.

Ethylbromazolam Review Recommends Class C Control Under Misuse of Drugs Act 1971

The Advisory Council on the Misuse of Drugs published a review on 14 April 2026 recommending that the novel benzodiazepine ethylbromazolam be made a Class C drug under the Misuse of Drugs Act 1971 and added to Schedule 1 of the Misuse of Drugs Regulations 2001. The recommendation is based on evidence of misuse and harms associated with the substance.

Professor Allsop, Professor Humphreys Join ACMD

The Advisory Council on the Misuse of Drugs (ACMD) has appointed Professor Steve Allsop and Professor Keith Humphreys as new members effective 1 February 2026. Professor Allsop is Emeritus Professor at the National Drug Research Institute, Curtin University, Australia. Professor Humphreys is the Esther Ting Memorial Professor in the Department of Psychiatry and Behavioural Sciences at Stanford University. These appointments follow 14 other experts joining the ACMD in 2025.

Register of ACMD Members' Interests and Occupations

The Advisory Council on the Misuse of Drugs (ACMD) maintains a register of interests for its council members, listing their occupations, employing organisations, and declared interests. The document was updated on 23 March 2026 to add a new trustee position for Roger Knaggs and on 17 March 2026 to update Professor Keith Humphreys' interests. Two new members, Professor Steve Allsop and Professor Keith Humphreys, were added with their declarations of interests on 2 February 2026. The register is an administrative transparency document for UK government advisory council members.

Government Response to ACMD 3 Medicines Reports on Drug Scheduling

The UK government agrees with ACMD recommendations to control three growth hormones (somapacitan, lonapegsomatropin, somatrogon) under Class C of the Misuse of Drugs Act 1971 and Schedule 4 (Part 2) of the Misuse of Drugs Regulations 2001. Ganaxolone will not be scheduled at this time. Zuranolone will be controlled under Class C and Schedule 4 (Part I) for treatment of post-natal depression.

Clinical Impact Awards 2026: Employers' Guide

The Advisory Committee on Clinical Impact Awards published guidance for the 2026 national Clinical Impact Awards competition in England and Wales. The guide sets out employer responsibilities in supporting NHS consultant doctors, dentists, and academic GPs through the application process. Employers are advised to read the guide before signing off applications and use it as a reference resource.

Appealing NCIA Decision Process Steps

ACCIA published guidance on 31 March 2026 outlining the process for appealing decisions on National Clinical Impact Award (NCIA) applications in England and Wales. The guidance specifies procedural grounds for appeal including discrimination, bias, conflicts of interest, or failure to follow standard evaluation processes. Medical and dental professionals must request an appeal within 28 days of receiving their award outcome notification.

ACCIA Sub-Committees and Their Role in Scoring NCIA Applications

The Advisory Committee on Clinical Impact Awards (ACCIA) published guidance on the role of 13 regional sub-committees in England in assessing National Clinical Impact Award (NCIA) applications. Sub-committee members (50% medical/dental professionals, 25% non-medical/lay members, 25% employers) score applications against standardised guidance, with top-ranked applicants referred to N3 national re-scoring. Separate sub-committees handle DHSC/arm's length body applications, highest-scoring regional applicants, and tied applications at cut-off points.

NHS Consultants Guide, National Clinical Impact Awards 2026

The Advisory Committee on Clinical Impact Awards published guidance on 31 March 2026 for NHS consultant doctors, dentists, and academic GPs in England and Wales on applying for national Clinical Impact Awards in 2026. The guidance covers eligibility requirements, the application process, scoring criteria, and transition arrangements for holders of National Clinical Excellence Awards moving to the new scheme.

SAMHSA Proposes PAIMI Program Performance Report Data Collection Under PRA

SAMHSA published a 60-Day Notice in the Federal Register seeking public comment on information collection activities for the Protection and Advocacy for Individuals with Mental Illness (PAIMI) Revised Annual Program Performance Report (PPR). The notice requests comments on whether the proposed data collection is necessary, accurate, and minimally burdensome. The OMB clearance for the current 2024-2025 PPR expires July 31, 2026, and SAMHSA is seeking approval for updates to the reporting requirements.

VICH GL8(R1) Draft Guidance: Stability Testing for Medicated Premixes (Revision 1)

The FDA announced availability of draft guidance for industry GFI #91 (VICH GL8(R1)) on stability testing for medicated premixes for veterinary use. Developed through the International Cooperation on Harmonisation of Technical Requirements for Registration of Veterinary Medicinal Products (VICH), this revision updates recommendations for stability testing of medicated premixes intended for oral administration following incorporation into animal feed. The draft is open for public comment until June 15, 2026.

Importation of Prescription Drugs Comment Request

The FDA has published a notice in the Federal Register announcing an opportunity for public comment on a proposed information collection related to the importation of prescription drugs. Under the Paperwork Reduction Act, the Agency seeks public input on existing information collection requirements. The comment period closes on June 15, 2026.

Agency Information Collection Activities: Submission for OMB Review; Comment Request

The Centers for Medicare and Medicaid Services (CMS) has published a notice under the Paperwork Reduction Act of 1995 announcing an opportunity for public comment on proposed information collections identified as CMS-10712 and CMS-10266. The notice invites interested persons to submit comments on the burden estimates and aspects of these proposed collections to the Office of Management and Budget (OMB). Comments must be received by May 18, 2026.

Medicaid and CHIP Generic Information Collection Activities: Proposed Collection; Comment Request

CMS published a Federal Register notice seeking public comment on generic information collection activities under OMB control number 0938-1148 (CMS-10398). The collections relate to Medicaid and CHIP State plan amendments, waivers, demonstrations, and reporting under a generic clearance process approved by OMB. Comments must be received by April 30, 2026.

Medicare IPPS FY 2027 Correction: Comment Deadline Changed from April 10 to June 9, 2026

CMS issued a correction to a previously published proposed rule for Medicare IPPS FY 2027. The correction fixes a typographical error in the DATES section, changing the public comment deadline from April 10, 2026 to June 9, 2026. The correction applies to the proposed rule published April 14, 2026 (FR Doc. 2026-07203, 91 FR 19312).

Annual Report for the 2021 Clinical Excellence Awards Round England and Wales

The Advisory Committee on Clinical Excellence Awards (ACCEA) published its annual report covering the 2021 awards round in England and Wales. The report details the committee's structure, governance processes, and analysis of award distribution. It also references a consultation on reform of the awards scheme. ACCEA advises the Department of Health and Social Care on Clinical Excellence Awards for NHS doctors.

Personal Statements From New National Clinical Excellence Award Recipients 2021

The Advisory Committee on Clinical Excellence Awards published personal statements from doctors who received National Clinical Excellence Awards in the 2021 round. The publication includes 543 pages of statements from new award holders detailing their clinical work and achievements. Applies to England and Wales.

National Clinical Impact Awards 2022: Resources for Applicants and Employers

The ACCIA secretariat published resources for the 2022 National Clinical Impact Awards (NCIA) scheme in England. Working with NHS Employers, the resources address key concerns about the reformed awards scheme and what the reforms mean for applicants and employers in practice. The 2022 awards opened on 27 April and closed on 22 June 2022.

ACCIA Application Portal Registration Opens 2022 Round

The Advisory Committee on Clinical Impact Awards and Advisory Committee on Clinical Excellence Awards (ACCIA) announced the opening of registration for the new ACCIA application portal for the 2022 award round. Applicants who plan to apply for an award must register for a new portal account, even if they have previously applied. Employers and nominating organisations will receive separate instructions via email. The portal is currently only accepting applications for new awards and will not display records of previous awards until data migration is completed.

Clinical Impact Awards Transition Arrangements for Award Holders

The Advisory Committee on Clinical Excellence Awards and Advisory Committee on Clinical Impact Awards announce transition arrangements for national Clinical Excellence Award holders moving to the new Clinical Impact Awards scheme. Transition provisions include pay protection and pensionability of full award value for the first award period. New awards will commence on 1 April following announcement of results.

REVIA Naltrexone 50mg Tablets Not Withdrawn for Safety Determination

FDA has determined that REVIA (naltrexone hydrochloride) tablets, 50mg, was not withdrawn from sale for reasons of safety or effectiveness. The drug, originally approved November 20, 1984, under NDA 018932 held by Teva Women's Health, Inc., was subject to a withdrawal request dated May 16, 2018. This determination permits FDA to continue approving abbreviated new drug applications (ANDAs) that refer to this listed drug product.

New Animal Drug Applications - Approval and Withdrawal Actions (Oct-Dec 2025)

FDA issued a final rule amending animal drug regulations to reflect application-related actions for NADAs, ANADAs, and CNADAs during October, November, and December 2025. The rule includes approval of original and supplemental applications, conditional approvals, sponsor changes, sponsor address changes, and withdrawal of approvals. Affected parties include sponsors and manufacturers of animal drug products. The rule is effective April 16, 2026.

FDA Determines Regulatory Review Period for UNLOXCYT Patent Extension

FDA Determines Regulatory Review Period for UNLOXCYT Patent Extension

Agency Information Collection Activities; Proposed Collection; Comment Request; Orphan Drugs

The FDA is announcing an opportunity for public comment on a proposed information collection associated with orphan drug requirements under the Paperwork Reduction Act of 1995. The Agency seeks input on existing collection requirements related to orphan drug designation. Comments must be submitted by June 15, 2026.

Determination That CHEWTADZY (Tadalafil) Chewable Tablets Were Not Withdrawn From Sale for Safety or Effectiveness

FDA determined that CHEWTADZY (tadalafil) chewable tablets, 5 mg, 10 mg, and 20 mg, were not withdrawn from sale for reasons of safety or effectiveness. This determination removes a statutory barrier and allows FDA to approve abbreviated new drug applications (ANDAs) for generic versions of the drug product if all other legal and regulatory requirements are met. The drug is subject of NDA 218527, held by B Better, LLC, which was initially approved on June 28, 2024.

Center for Scientific Review Notice of Closed Meetings

The National Institutes of Health Center for Scientific Review announces five closed virtual meetings scheduled for May 13-14, 2026. The meetings will review and evaluate grant applications and contract proposals for programs including Behavioral Neuroscience training, the REDS Program Brazil Field Center, Transfusion Laboratory Studies, and Research Enhancement Award programs. Meetings are closed pursuant to the Federal Advisory Committee Act to protect confidential trade secrets, commercial property, and personal information.

E. coli O26 Outbreak Linked to Pillsbury Brand Pizza Pops

PHAC issued an update on an active E. coli O26 outbreak linked to certain Pillsbury brand Pizza Pops products. The outbreak has resulted in 29 illnesses across 7 provinces, with 7 hospitalizations and no deaths reported. A food recall is in effect for affected products, and PHAC advises consumers not to consume, use, sell, serve, or distribute the recalled items.

Dr. Joss Reimer Appointed Chief Public Health Officer for Three-Year Term

The Government of Canada appointed Dr. Joss Reimer as Chief Public Health Officer (CPHO) for a three-year term commencing April 1, 2026. Dr. Reimer succeeds Dr. Theresa Tam and brings extensive public health expertise including experience as past President of the Canadian Medical Association and Chief Medical Officer for the Winnipeg Regional Health Authority. She takes the role at a time when Canada faces multiple public health challenges including measles resurgence, avian influenza A(H5N1), HIV, tuberculosis, and the illegal drug crisis.

HPTA Biosecurity Amendments Receive Royal Assent

The Public Health Agency of Canada announced that amendments to the Human Pathogens and Toxins Act (HPTA) received Royal Assent on March 27, 2026. The amendments modernize biosecurity oversight for scientific research by adding provisions for remote technology access to containment facilities, clarifying roles and responsibilities for regulated parties, improving security screening requirements, reducing incident reporting thresholds, and modernizing compliance and enforcement measures. Affected entities include universities, hospitals, pharmaceutical companies, and food industry quality control operations.

Salmonella Outbreak Linked to Pistachios - 155 Illnesses, 24 Hospitalizations

The Public Health Agency of Canada (PHAC) is reporting an active Salmonella outbreak investigation linked to various brands of pistachios and pistachio-containing products. The outbreak has resulted in 155 reported illnesses and 24 hospitalizations across six provinces. The Canadian Food Inspection Agency (CFIA) has issued food recalls for affected products.

VIAP Launches April 1 for Vaccine Injury Support

The Public Health Agency of Canada (PHAC) announced it will begin administering the Vaccine Impact Assistance Program (VIAP) on April 1, 2026, replacing the third-party administrator Oxaro Inc. VIAP provides financial support to Canadians (except Quebec) who experienced serious and permanent injury from Health Canada authorized vaccines administered in Canada on or after December 8, 2020. PHAC will work to address the existing backlog of applications while improving consistency and transparency of the claims process.

Bispecific Anti-TRAILR2 and Anti-CDH17 Binding Molecules for Cancer Treatment - EP3559040A2

The EPO published patent application EP3559040A2, filed by Boehringer Ingelheim International GmbH, covering bispecific binding molecules that simultaneously target TRAILR2 (TNF-related apoptosis-inducing ligand receptor 2) and CDH17 (cadherin 17) for the treatment of cancer. The patent application was published on April 8, 2026 and is classified under IPC categories C07K 16/28, A61K 39/395, A61P 35/00, and C12N 15/62. The application designates all EPO contracting states covering major European pharmaceutical markets.

Immunoglobulin antibody against RSV prefusion F protein, published 8th Apr

Immunoglobulin antibody against RSV prefusion F protein, published 8th Apr

PHARMACEUTICAL COMPOSITIONS COMPRISING POH DERIVATIVES

The European Patent Office granted Patent EP3244930A1 to the University of Southern California on April 8, 2026. The patent covers pharmaceutical compositions comprising POH derivatives for therapeutic applications including cancer treatment. The patent is designated across 38 European member states including DE, FR, GB, IT, ES, NL, BE, and others.

Bi-Specific Cancer Treatment Constructs with Different Epitope Binding

The European Patent Office published patent application EP3484516A1 assigned to Fred Hutchinson Cancer Center on April 8, 2026. The patent covers bi-specific binding domain constructs with different epitope binding properties for treating cancer. The technology falls under IPC classifications A61K 39/395, C07K 16/28, and C12N 15/09, with designated states covering major European markets.

TLR4 Antagonist Patent for Multiple Myeloma Treatment EP3558323A1

The European Patent Office granted patent EP3558323A1 for specific TLR4 antagonists in the treatment of multiple myeloma. The patent applicants include Etablissement Français du Sang, CNRS, Université Paul Sabatier Toulouse III, and INSERM. Designated states cover all EU member states plus other EPC contracting states.

Novel Recombinant Protein UK114 in Stable Polymer Form for Tumour Treatment

The European Patent Office granted Patent EP3554639A1 to Alberto Bartorelli Cusani for a novel recombinant protein UK114 in stable polymer form designed for the treatment or prevention of malignant solid and systemic tumours. The patent covers pharmaceutical compositions containing the recombinant protein and methods of treatment. The patent is classified under A61K 38/50 and related pharmaceutical categories.

Polyglutamated Antifolates and Uses Thereof (EP3496757A1)

The European Patent Office published patent application EP3496757A1 for polyglutamated antifolates and their therapeutic uses, filed by L.E.A.F Holdings Group LLC. The patent covers compositions for treating cancer and inflammatory conditions. The application was published April 8, 2026, designating 36 European states including Germany, France, the United Kingdom, Italy, Spain, and other EU member states. No compliance deadlines or penalties are specified.

Fibrous Dosage Form EP3500242A1

The European Patent Office published patent application EP3500242A1 titled 'Fibrous Dosage Form' on April 8, 2026. The patent application, filed by applicant Aron H. Blaesi with inventors Blaesi and Nannaji Saka, covers pharmaceutical dosage formulations classified under IPC A61K. The application designates multiple European member states for patent protection.

EP3283091A1 - Berry Extraction Method Using Alkaline Magnesium Compound

The European Patent Office granted Patent EP3283091A1 to inventor Reijonen, Mika Tapio. The patent covers a method of extracting berries or fruits using an alkaline magnesium compound for use in pharmaceutical, herbal, nutritional, or cosmetic ingredients. The patent is valid in 38 designated European states.

UK NSC Meeting Agenda Covers Prostate, Bladder, and Targeted Screening

The UK National Screening Committee published its meeting agenda for 26 March 2026. The agenda included discussions on prostate cancer screening, bladder cancer screening, targeted screening workstreams, and an effectiveness review of the NHS Infectious Diseases in Pregnancy Screening Programme. No new screening recommendations or policy changes were announced.

Blood Spot Task Group Projects and Outputs Status Summary

The UK National Screening Committee published transparency data on Blood Spot Task Group (BSTG) projects and outputs on 9 February 2026, updated 18 March 2026. The BSTG focuses on generating practical outputs related to blood spot screening methodology and research. This publication summarises the status of BSTG projects and their outputs, including expected finish dates added to two ongoing projects. No new compliance obligations are created by this document.

UK NSC Privacy Notice on Personal Data

The UK National Screening Committee published a privacy notice explaining how it collects, uses, and shares personal data from individuals who subscribe to UK NSC recommendations or participate in public consultations. The notice details the types of personal data processed (name, email, job title, employer, opinions, and sensitive personal data), the legal basis for processing under UK GDPR Article 6(1)(e) and Article 9(2)(g), and data protection measures including security controls and staff training. Data may be shared with UK NSC secretariat staff, policy teams, and committee members.

UK NSC Public Consultations Guide, Current and Closed

The UK National Screening Committee (UK NSC) provides a guide to its public consultations on screening recommendations. Three consultations are currently open: antenatal hepatitis C screening (deadline June 3, 2026), newborn biliary atresia screening (deadline May 20, 2026), and targeted antenatal HTLV-1 screening (deadline May 13, 2026). Stakeholders and members of the public can submit comments via the UK NSC website.

Prostate Cancer Screening Consultation Closes

The UK National Screening Committee (UK NSC) announced that its 12-week public consultation on prostate cancer screening has closed as of 24 February 2026. The consultation sought feedback on a 2025 modelling study examining screening impacts across all men in the UK, Black men, men with BRCA1/BRCA2 variants, and men with relevant family cancer history. Submitted responses will be analysed at the committee's March meeting before a final recommendation is made to ministers.

Oligonucleotides for Inducing Paternal UBE3A Expression - Angelman Syndrome Treatment

USPTO granted patent US12596118B2 to Hoffmann-La Roche Inc. covering oligonucleotides capable of inducing expression of ubiquitin-protein ligase E3A (UBE3A) from the paternal allele for treatment of Angelman syndrome. The 30 claims target the suppressor of the UBE3A paternal allele via hybridization to SNHG14 long non-coding RNA downstream of SNORD109B.

INHIBITORS OF TRPC6 - Boehringer Ingelheim International GmbH

The European Patent Office published patent application EP3752503A1 for TRPC6 inhibitors assigned to Boehringer Ingelheim International GmbH. The patent covers therapeutic compounds for cardiovascular, respiratory, and neurological applications. The application designates all EPC contracting states including Germany, France, United Kingdom, Italy, and Spain.

EP3759090A1 Novel Therapeutic Compounds by Inflazome Limited

The European Patent Office published patent application EP3759090A1 for novel therapeutic compounds filed by Inflazome Limited. The patent covers heterocyclic compounds with IPC classifications including C07D derivatives and A61P therapeutic activity (anti-inflammatory/analgesic). Designated states include all EU member states plus associated countries. The publication marks the grant of patent rights for these novel compounds.

Novel Anti-inflammatory Compounds - EP3759089A1

The European Patent Office published patent application EP3759089A1 for novel anti-inflammatory compounds developed by Inflazome Limited. The patent covers compounds classified under C07D 401/12 with therapeutic applications (A61P 29/00). Validated in designated contracting states including Germany, France, United Kingdom, Italy, Spain, and other EU member states.

Methods for Using Low-Dose Colchicine After Myocardial Infarction (EP3821909A1)

The European Patent Office published application EP3821909A1, titled 'Methods for Using Low-Dose Colchicine After Myocardial Infarction.' The application, filed by Institut de Cardiologie de Montréal, claims methods of treating patients with low-dose colchicine following myocardial infarction. The published application covers 38 designated European states.

Use of Chimeric Antigen Receptor-Modified T Cells to Treat Cancer

The European Patent Office granted Patent EP3660029A1 to The Trustees of the University of Pennsylvania covering chimeric antigen receptor (CAR)-modified T cells for cancer treatment. The patent names inventors Carl H. June, Bruce L. Levine, David L. Porter, Michael D. Kalos, and Michael C. Milone. The patent covers methods for treating cancer using CAR-modified T cells, with designations extending across 35 European states.

TPEC Program Performance Measures Information Collection Request

HRSA announced a proposed Information Collection Request under the Paperwork Reduction Act for the Transforming Pediatrics for Early Childhood (TPEC) Program Performance Measures. The collection would require TPEC funding recipients to report standardized annual performance measures demonstrating program impact on young children and families served by TPEC-funded pediatric practices. Public comments on the burden estimate and other aspects of the collection are requested by June 15, 2026.

EP3558428A1 Medicament Delivery Device

The European Patent Office published EP3558428A1, a patent for a medicament delivery device filed by Sanofi-Aventis Deutschland GmbH. The patent was published on April 8, 2026, with inventors Verlaak and Melzi. The publication covers device mechanisms classified under A61M 5/315, A61M 5/145, and A61M 5/31.

Brain Function Visual Effects Patent, Dragonfly Optics, 8th Apr

Brain Function Visual Effects Patent, Dragonfly Optics, 8th Apr

Devices for Estimating Regional Metabolic Rate of Organs Based on Heat Generation and for Estimating Regional Blood Flow for Tissue Volume Perfused

EPO granted patent EP3244850A2 to Hybernia Medical LLC. The patent covers devices for estimating regional metabolic rate of organs based on heat generation and for estimating regional blood flow for volumes of tissue perfused. The invention relates to medical devices using thermal and blood flow measurements for organ analysis.

Intubation Device European Patent Application EP3397132A1

The European Patent Office published European patent application EP3397132A1 for an intubation device, filed by inventors Bartozzi, Lennon, and Keith. The patent application covers medical device technology classified under A61B and A61M IPC categories. The publication designates multiple European member states for patent protection.

Syringe Assembly Packaging Patent, Terumo Kabushiki Kaisha

The European Patent Office published European patent application EP3431126A1 for Terumo Kabushiki Kaisha, covering a syringe assembly, syringe assembly packaging, and prefilled syringe. Inventors are Masafumi Takemoto and Hitoshi Okihara. The patent application is classified under IPC A61M 5/32 (syringes/injections) with designations extending to 31 European states including DE, FR, GB, IT, ES, NL, and others.

Biocorp Production SAS - Dose Control System for Injectable-Drug Delivery Devices (EP3573687A1)

The European Patent Office published patent application EP3573687A1 for Biocorp Production S.A.S., covering a dose control system for injectable-drug delivery devices and associated methods of use. The patent application (filed under IPC classifications A61M 5/20 and A61M 5/315) was published April 8, 2026. The application designates all EU member states and extended states including Switzerland, Norway, and Turkey.

Sensor Enabled Wound Monitoring and Therapy Apparatus

The European Patent Office published application EP3454918A1 for Smith & Nephew plc on April 8, 2026. The patent covers a sensor enabled wound monitoring and therapy apparatus with IPC classifications A61B 5/00, A61F 13/05, A61F 13/00, and A61M 1/00. The application designates all relevant EPC contracting states including AT, BE, DE, ES, FR, GB, IT, NL, and others.

Medicament Injection Device - Sanofi-Aventis EP3532132A1

The European Patent Office granted Sanofi-Aventis Deutschland GmbH Patent EP3532132A1 for a medicament injection device. The patent application was published on April 8, 2026, with inventors including HALM, Markus. Designated states cover all EU member states plus other European countries.

EP3576821A1 Medication Delivery Assembly, Norton Healthcare

The European Patent Office published patent application EP3576821A1 for an assembly for a medication delivery device, filed by Norton Healthcare Limited. The application was published on April 8, 2026, under IPC classifications A61M 5/31 and A61M 5/315. The application designates multiple European states including Germany, France, United Kingdom, Italy, and Spain.

Therapeutic Exosomes Nanoelectroporation Patent EP3661485A1

The European Patent Office published patent application EP3661485A1 titled 'Method for Producing Therapeutic Exosomes from Nanoelectroporation and Other Non-Endocytic Cell Transfection.' The patent is assigned to Ohio State Innovation Foundation with inventors Lee Ly James, Shi Junfeng, and Yang Zhaogang. The invention relates to methods for producing therapeutic exosomes using nanoelectroporation and non-endocytic cell transfection techniques.

Fluid Drainage or Delivery Device for Treatment Site - Aroa Biosurgery EP3691737A1

The European Patent Office published patent application EP3691737A1 for Aroa Biosurgery Limited, covering a fluid drainage or delivery device for treatment sites. The invention includes claims for medical device components classified under A61M and A61L. The patent designates multiple European states including DE, FR, GB, IT, NL, ES, and others.

997 Measles Cases, No New Cases Since March - Outbreak Update

South Carolina DPH reports no new measles cases since March 17, keeping the Upstate outbreak total at 997. No individuals are currently in quarantine or isolation. If no new cases are reported, the outbreak will be declared over on April 26, following a 42-day period with no new cases.

Artri Ajo King Tablets Contain Undeclared Prescription Medicines

TGA Laboratory testing identified Artri Ajo King tablets as containing undeclared diclofenac and dexamethasone, both prescription-only medicines in Australia. The TGA has issued a safety advisory warning consumers to stop using the product and is coordinating with the Australian Border Force to seize and destroy shipments at the border. Supply of these products without declared prescription medicines is illegal under Australian therapeutic goods legislation.

Spevigo Authorization Transfer to LEO, Delayed Leaflet

Swissmedic notifies healthcare professionals that the marketing authorization for Spevigo (spesolimabum, authorization no. 68625) was transferred from Boehringer Ingelheim (Schweiz) GmbH to LEO Pharmaceutical Products Sarath Ltd. effective 02.03.2026. To prevent supply disruption, packages with outdated package leaflets remain in circulation until the reprint is completed. These leaflets have not yet been updated with the latest approved safety information.

Boil Water Advisory Issued for the City of Humboldt, Allen County

The Kansas Department of Health and Environment (KDHE) has issued a boil water advisory for the City of Humboldt public water supply system in Allen County. The advisory was issued due to a loss of pressure, which may result in loss of chlorine residuals and bacterial contamination. Customers should boil water for one minute prior to drinking or food preparation, or use bottled water, until conditions are resolved and testing confirms safety.

Stryker Updates Use Instructions for Patient-Fitted TMJ Reconstruction Prostheses

Stryker issued an urgent medical device correction for TMJ Unilateral and Bilateral Implants (catalogs CHG010, CHG024, CHG031, CHG020, CHG026, CHG032). The FDA identified this as the most serious recall type due to screw hole positioning discrepancies that may cause recommended screw lengths to exceed bone thickness, risking cranial vault penetration. One serious injury has been reported. Healthcare providers should continue monitoring patients per follow-up protocols and contact Stryker if affected devices remain in unused inventory.

Correction for Philips Trilogy Evo Platform Ventilators - Non-Pneumatic Nebulizer Restrictions

FDA issued a Class I recall for Philips Trilogy Evo Platform ventilators (models DS2110X11B, DS2200X11B, DS2100X11B, DS2000X11B) due to risks from non-pneumatic nebulizer use causing tidal volume discrepancies and potential therapy under-delivery. Affected parties must update all devices to software version 1.05.15.00 and stop all use of non-pneumatic nebulizers. Failure to correct devices may result in serious injury or death.

Welcome Speech at 80th Anniversary of National Blood Programme

HSA CEO Adj Prof (Dr) Raymond Chua delivered a welcome speech at the 80th anniversary of Singapore's National Blood Programme. The speech recognises donors, partners, and volunteers who have contributed to the programme since its establishment, as well as the ongoing partnership with the Singapore Red Cross. HSA's Blood Services Group and laboratory staff are commended for maintaining internationally recognised standards in transfusion medicine.

Singapore National Blood Programme Marks 80 Years

The Health Sciences Authority (HSA) and Singapore Red Cross marked the 80th anniversary of the National Blood Programme at a commemorative event. Minister for Health Ong Ye Kung announced new donor recognition initiatives including a Healthpoints programme launching in H2 2026 and the '80 for 80' Blood Donation Marathon to encourage corporate blood donation drives. HSA projects Singapore's blood demand could outstrip supply by 2035 as youth donations have declined by more than half over the past decade.

New Drug Approvals February 2026

The Health Sciences Authority (HSA) Singapore announced new therapeutic product approvals granted in February 2026. The announcement lists newly approved therapeutic products and new indications approved for registered therapeutic products. Healthcare professionals and industry members are directed to the listing for details.

Artificial Sweat Composition, EP3355853A1, Apr 08

Artificial Sweat Composition, EP3355853A1, Apr 08

Pharmaceutical Composition Comprising Lipoic Acid and Taurine as Osmoprotective Agent

The EPO granted Patent EP3297733A1 to Dulcis Health Science for a pharmaceutical composition combining lipoic acid and taurine as an osmoprotective agent. The patent, published April 8, 2026, lists inventors Claret, Martine, Claret, Claude, and Chatard-Baptist, Caroline, with designations covering all 31 European Patent Convention member states.

Long-Acting Injectable Formulations Comprising an Isoxazoline Active Agent (EP3261617A1)

The European Patent Office published European patent application EP3261617A1 for Boehringer Ingelheim Vetmedica GmbH covering long-acting injectable formulations comprising isoxazoline active agents. The application classifies under IPC codes A61K 31/422, A61K 31/42, A61K 9/00, and A01N 43/80. The application designates 36 European contracting states including Germany, France, United Kingdom, Italy, Spain, and other EU member states.

Shiseido Skin Glow Evaluation Method Patent EP3219302A1

The European Patent Office published Shiseido Company Ltd.'s patent application EP3219302A1 covering methods for evaluating skin glow, methods for examining skin glow improving agents, and skin glow improving compositions. The patent application was published on April 8, 2026, designating 37 European states including DE, FR, GB, IT, ES, and others. The application includes inventors Masuda Yuji, Yagi Eiichiro, and Kuwahara Tomohiro.

Cinnamyl Alcohol Derivative for Appetite Reduction

The European Patent Office published application EP3474833A1 for Symrise AG covering a cinnamyl alcohol derivative for reducing appetite and generating satiety. The invention lists Veronika Somoza, Barbara Lieder, Katrin Geissler, Joachim Hans, Kathrin Langer, Jakob Peter Ley, and Sabine Widder as inventors. The application classifies under A61K 31/015, A61K 31/185, and A61K 31/215. Validated designated states include DE, FR, GB, IT, ES, NL, and other EPC contracting states.

Sixth Circuit Upholds DOL Home Care Overtime Rule Post-Loper Bright

The Sixth Circuit in DOL v. Americare Healthcare Services upheld the DOL's 2013 rule requiring third-party home care agencies to pay overtime to live-in caregivers, rejecting arguments that Loper Bright invalidated the regulation. The court found Congress expressly delegated authority to the DOL to define FLSA companionship exemptions, so the rule remains valid. The decision comes as the DOL has separately proposed rescinding the same rule effective July 2025.

FY 2027 Budget Reconciliation Could Reshape Health Policy

The President submitted FY 2027 budget proposals to Congress on April 3, 2026, with Senate Budget Committee Chairman Lindsey Graham expected to move a budget resolution the week of April 20 containing reconciliation instructions. Budget reconciliation allows Congress to advance spending and policy changes with a simple 51-vote majority in the Senate. Health care provisions that were dropped from prior legislation, including Medicaid penalties, HSA/HRA expansions, and CHOICE arrangements, may be reconsidered in future reconciliation bills.

FDA Reassessing Dietary Supplement Framework, Ingredient Scope, Manufacturing Changes

The FDA held a public meeting on March 27, 2026 to reassess its dietary supplement regulatory framework under DSHEA. The agency is evaluating the scope of 'dietary substance' definitions, including novel ingredients and emerging production technologies such as synthesis, cell culture, precision fermentation, and recombinant methods. FDA is also considering when manufacturing changes may trigger new regulatory scrutiny or NDI submissions, and how the GRAS pathway intersects with dietary supplement regulation.

CMS Issues Contract Year 2027 Final Rule and Rate Announcement for Medicare Advantage and Part D

CMS released the CY2027 Final Rule for Medicare Advantage and Medicare Part D along with the MA Capitation Rates and Part C and Part D Payment Policies Rate Announcement. The Final Rule finalizes without modification much of the CY2027 proposed rule and unexpectedly includes provisions from the CY2026 proposed rule not previously finalized. CMS clarified the non-allowable SSBCI list to permit hulled hemp seed, hemp seed protein powder, and hemp seed oil as allowable items while maintaining prohibition on cannabis products illegal under state or federal law.

Louisiana Anticipates CMS Approval for 1115 Prison Reentry Demonstration Waiver

Louisiana Department of Health announces anticipation of CMS approval for its Section 1115 Medicaid Reentry Demonstration Waiver. Louisiana was the first state to align its waiver with new federal budget-neutrality requirements under Sec. 71118 of H.R. 1 (OBBBA), effective January 1, 2027. The waiver aims to improve health outcomes for individuals transitioning from incarceration by connecting them to Medicaid coverage and pre-release services.

2024 PMPRB Annual Report Shows $22.1B Patented Medicine Sales

The Patented Medicine Prices Review Board (PMPRB) has tabled its 2024 Annual Report in Parliament. The report documents $22.1 billion in sales of patented medicines in Canada for the reporting period. PMPRB continues its role as Canada's federal board responsible for reviewing patented medicine prices to ensure they are not excessive.

Public Drug Plan Spending Rose $3.4B Over 5 Years Driven by High-Cost Drugs

The PMPRB released its CompassRx 10th edition report showing Canadian public drug plan prescription spending grew 7.4% in 2022/23 to $14.1 billion from $13.2 billion in 2021/22. Over five years (2017/18 to 2022/23), total spending rose by $3.4 billion with a compound annual growth rate of 5.9%. Drugs costing over $10,000 annually were used by less than 3% of beneficiaries yet accounted for over one-third of total drug costs.

PMPRB Releases New Guidelines for Drug Price Monitoring Effective January 1

The Patented Medicine Prices Review Board (PMPRB) has released new guidelines governing how staff monitor and review patented drug prices in Canada. The guidelines establish updated procedures for price excessive price hearings and related administrative processes. The new guidelines take effect January 1, 2025.

PMPRB News Archive Results Page

The Patented Medicine Prices Review Board (PMPRB) published a news archive search results page displaying 79 results. The page serves as a navigational interface to the PMPRB's published news content on Canada.ca.

Proposed Practice Directions on Mode of Hearings, Document Exchange, Motions, Filing, AI Use, Virtual Proceedings

The Patented Medicine Prices Review Board (PMPRB) is consulting on seven proposed practice directions to modernize its hearing procedures. The directions address mode of hearings (defaulting to paper hearings for evidentiary portions), document exchange facilitation, motion standardization, electronic filing and page limits, expedited failure-to-file proceedings, use of artificial intelligence in proceedings, and virtual proceedings. Stakeholders may submit comments on these proposed directions.

Bernier 2009 FDA Regulatory Proceeding Citation

A 2009 FDA regulatory proceeding authored by Bernier has been cited and made available through the Regulations.gov docket system as part of a public filing (FDA-2026-P-3869-0069). The original document content is restricted due to copyright limitations. This reference represents an historical FDA regulatory proceeding that is being made accessible for regulatory record purposes.

Vessey 1986 Scientific Reference as FDA Background Material

A 1986 scientific reference authored by Vessey has been submitted as background material in connection with FDA submission FDA-2026-P-3869. This document provides supporting scientific context for the regulatory submission. The reference appears to be a peer-reviewed publication submitted to provide scientific support for safety or efficacy determinations in the associated FDA filing. No independent compliance obligations, deadlines, or enforcement actions are created by the submission of this reference document.

FDA Package Insert NDA 021323 Background Material

FDA has released background material supporting NDA 021323, which pertains to a package insert for a pharmaceutical product. The document was submitted through the FDA pre-market approval process and is part of the agency's review documentation. This background material is available for public access on Regulations.gov.

DC Emancipation Day 2026, District Services Modified

DC Department of Health announced modified District government services for DC Emancipation Day on Thursday, April 16, 2026. Low-barrier homeless shelters, mental health crisis services including the 988 helpline and DC Stabilization Center, select public libraries, and Department of Parks and Recreation outdoor facilities will remain open. No new compliance obligations are imposed.

Nitrous Oxide Chargers: Sold for Inhalation Without Market Authorization (DIN) - Type I Recall

Health Canada has issued a Type I recall (RA-81896) for nitrous oxide (N2O) chargers sold by DOODLEZ, Gold Whip, and Whip-it! brands, all marketed for inhalation without market authorization (DIN). The recall affects flavored and unflavored gas chargers distributed by Mega Sphere Trading (Calgary, AB). Health Canada warns consumers not to inhale nitrous oxide products for recreational purposes due to serious health risks.

Medtronic SynchroMed Programmer Application Software Recall, Type II

Health Canada has issued a Type II recall for Medtronic's SynchroMed Clinician Programmer Application (CP app) model A810 due to a software sequencing issue affecting flex dosing programming for SynchroMed 8637 and 8667 infusion pumps. When flex dosing steps are added overlapping and out of chronological order, the app may fail to reorder them correctly, potentially causing infusion steps to be delivered at incorrect times, leading to missed doses, underdosing, or shifted dose timing without immediate alerts. Eleven complaints have been reported globally. Affected parties should contact Medtronic for information and guidance.

i-STAT EG7+ Cartridge Recall for pH Errors

Health Canada has issued a Type II recall for Abbott Point of Care Inc.'s i-STAT EG7+ Cartridge due to a manufacturing defect causing inaccurate pH and pCO2 readings. Affected lots (N25209, Model 03P76-25) may report higher than expected pCO2 and lower than expected pH results, potentially leading to inappropriate clinical interventions. Healthcare providers should immediately discontinue use of these cartridges for pH and pCO2 testing and contact the manufacturer for additional information.

Bard and Daig Steerable Diagnostic EP Catheter Recall for Sterility Breach

Health Canada issued a Type II recall for Bard Dynamic Deca Steerable Diagnostic EP Catheters (model 201101) and Daig Livewire Steerable Diagnostic EP Catheters (models 401904, 401575) due to breached sterile barriers on the chevron seal side of the primary Tyvek pouch. Stryker Sustainability Solutions received complaints reporting EP catheter devices with compromised sterile packaging. Affected lot numbers exceed 10; healthcare providers are advised to contact the manufacturer for specific lot information and next steps.

Halozyme Hypercon Therapeutic Biologics Delivery Patent US12600763B2

USPTO granted patent US12600763B2 to Halozyme Hypercon, Inc. covering compositions and methods for delivering therapeutic biologics for disease treatment. The patent comprises 18 claims for particles containing therapeutic biologics suspended in a liquid carrier, with priority to an August 2022 filing date.

Tulane Patent for Therapeutic Compound Conjugates US12599674B2

The USPTO granted Patent US12599674B2 to The Administrators of the Tulane Educational Fund covering inventive therapeutic compound conjugates, pharmaceutical compositions, and related methods of treatment and manufacture. The patent, filed June 24, 2025, under application 19247100, contains 23 claims classified under A61K and A61P (oncology).

Jason Jimenez Surgical Assistant License Restricted

On April 2, 2026, the Texas Medical Board temporarily restricted the surgical assistant license of Jason Phillip Jimenez (Lic. No. SA00556) following his arrest on October 1, 2025, for one count of Aggravated Sexual Assault of a Child, a first-degree felony. The restriction is effective immediately and prohibits Mr. Jimenez from treating patients under 18 years of age and requires direct physician observation during all surgical assistant duties. The temporary restriction remains in place until further Board action.

TMB Restricts Austin Doctor for Inappropriate Text Messages

A disciplinary panel of the Texas Medical Board temporarily restricted, without notice, the Texas medical license of Dr. David Anthony Rodriguez (Lic. No. Q4504) effective April 8, 2026. The panel found Dr. Rodriguez engaged in repeated unprofessional conduct and sent a patient inappropriate and sexually explicit text messages. The restriction prohibits Dr. Rodriguez from practicing medicine on female patients, including via telemedicine. The temporary restriction remains in place until the Board takes further action.